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Polysaccharide-peptide (PSP) is a protein-bound polysaccharide 
isolated from the basidiomycete Coriolus versicolor (strain Cov-1), and has 
been used recently in China as an immunomodulatory agent against various 
kinds of tumor in both experimental studies and clinical trials (Yang et al, 
1992). Preliminary studies have also shown that PSP is effective in protecting 
the liver from hepatotoxins in laboratory animals, and may be useful in the 
treatment of hepatitis. The paracetamol-model of drug-induced toxicity was 
used in this study. Paracetamol (4-acetyl-/7-aminophenol, APAP) is one of the 
most commonly used antipyretic-analgesic agent, and is hepatotoxic when 
APAP is taken overdose. The metabolism and toxicity of APAP are well 
understood, and hence it is ideal for investigating the possible drug-drug 
interactions of APAP with PSP through the biotransformation reactions of 
APAP. This may offer some preliminary insights on the pharmacological 
effects of PSP, and is particularly relevant to the proposed use of PSP as an 
adjuvant in cancer chemotherapy. 
Glutathione is important for the regulation of cellular redox balance, 
leukotriene metabolism, cell proliferation and immune function. In this study, 
PSP (300 mg/kg, i.p.) decreased hepatic total glutathione (GSH + GSSG) 
level by 18 % at 6 hr after its administration into rats. Accompanying the 
hepatic loss of glutathione, the glutathione levels in blood were slightly 
increased showing that PSP might enhance the hepatic export of glutathione 
into systemic circulation. When PSP (100-400 mg/kg/day, i.p.) was 
administered into rats for 7 days, there were significant decreases by up to 30 
% of total glutathione (GSH + GSSG) levels at the higher doses. Furthermore, 
there was a dose-dependent decrease of hepatic reduced glutathione (GSH) by 
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9 % to 40 % when increasing doses of PSP were administered into rats. 
However, when PSP (300 mg/kg, i.p.) was administered into rats 6 hr after the 
APAP administration (1.5 g/kg, p.o.), discharges of aminotransaminases from 
liver 24 hr after APAP administration were greatly reduced (by 67 %), 
indicating that PSP co-administration had a protective effect on the liver. Co-
administration of PSP with APAP reduced the oxidative stress in liver (by 56 
o/o), and might protect the liver from APAP-toxicity through this mechanism. 
PSP also decreased the covalent binding of ^^C-APAP to microsomal proteins 
in vitro dose-dependently (25-63 %). The covalent binding of ^^C-AP^ was 
again decreased (by 28 %) with microsomes obtained from rats which had 
been pretreated with PSP (100 mg/kg/day, i.p.) for 7 days. When PSP (200 
mg/kg bolus, i.v.) was administered into rats 30 min before APAP 
administration (100 mg/kg bolus, i.v.), the total systemic clearance of APAP 
was significantly increased. The maximum concentration (Cmax) of APAP-
glucuronide conjugate in plasma was increased by 34 % after the PSP co-
administration. Furthermore, the Cmax of sulphate conjugate in plasma and bile 
were also elevated (by 37 % and 240 %, respectively) when PSP was co-
administered with APAP. The amounts of sulphate and glucuronide 
metabolites of APAP were increased by PSP co-administration such that less 
of the APAP dose would undergo P450 oxidation to the chemically-reactive 
metabolite. 
Although PSP reduced glutathione levels in liver, the reduction might 
exist as an intermediate step in which PSP protected against APAP-
hepatotoxicity. Since PSP decreases hepatic glutathione levels but increases 
the sulphation of APAP, and glutathione and sulphate share cysteine as a 
common precursor; it is logical to postulate that PSP may decrease the 
glutathione level in liver and hence increases the supply of co-factor for 
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sulphation of APAP to occur. The sulphation of APAP may then act as an 
important first-line defense against APAP-toxicity. 
In summary, PSP protects against APAP-induced hepatotoxicity by 
decreasing the covalent binding of the chemically-reactive metabolite of 
APAP. The increases in sulphation and glucuronidation of APAP by PSP may 
also contribute to this protection effect. 
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1.1 Polysaccharide-peptide (PSP) 
Polysaccharide-peptide (PSP) is a protein-bound polysaccharide isolated 
from deep-cultured mycelia of Coriolus versicolor (strain Cov-1) in Shanghai 
Teachers University, China. PSP has been shown to be effective as an 
anticarcinogen and an immunomodulator. PSP (500 |ig/ml) was effective in 
inhibiting the growth of P388 leukemia cells (90-96 %) in vitro. Using a high 
concentration of PSP (1 mg/ml), almost all the P388 leukemia cells in culture 
were killed. Intraperitoneal administration of PSP (50 mg/kg) to mice inhibited 
the growth of sarcoma 180 cells (44-68 %), and when the mice were fed with 
PSP (1000 mg/kg) the growth of sarcoma 180 cells was also inhibited, but to a 
lesser degree (35-52 %). PSP (1 mg/ml) also inhibited the growth of human 
gastric cancer, lung cancer, lymphoma and mononuclear leukemia cells 
cultivated in vitro (Yang et al., 1991). 
The full pharmacology and toxicology profiles of PSP have yet to be 
established, but some of its properties have been recently reported (Anonymous, 
1993). It is reported that PSP reverses the decrease of appetite in mice taking the 
chemotherapeutic drugs for cancer. The body weights and the lymphocyte 
numbers in blood are also increased by PSP treatment. When PSP is administered 
1 
either i.v. or i.p. to mice, the pain reflex due to chemical irritation (acetic acid or 
K+) or heat irritation is also markedly reduced. The oral dose LD50 of PSP in rats 
is greater than 18 g/kg, indicating its relatively wide safety margin. When rats 
were administered orally with PSP at 50 to 100 times of its clinical dosages (0.4-
16 g/kg) for 6 months, no adverse obvious effect on their growth and 
development, biochemical index of blood and cardiogram, nor abnormality in 
tissue was observed. When PSP was administered orally to mice (100 times its 
clinical dosage), no abnormal change could be observed in their sperm nor 
abnormal effects on the mother and the state of the fetus before and after birth for 
2 generations. Both metaphase chromosome aberrations test and micronuclear 
test per mill of the marrow cells showed no difference between the control and 
experimental animals after the PSP treatment. 
The physical and chemical properties of PSP have been investigated by a 
research team (Q.Y. Yang, S.C. Yong and X.T. Yang) from Shanghai Teachers 
University and Y.F. Zhou from Northeast China Teachers University in China 
(unpublished data). PSP is a protein-bound polysaccharide with a molecular 
weight (m.w.) of 100 kDa. The molecule has 21 % of protein content, and 18 
different amino acids (relative proportion) have been identified, including 
aspartic acid (0.4), threonine (0.23), serine (0.32), glutamic acid (0.58), proline 
(0.10)，isoleucine (0.22), leucine (0.24)，tyrosine (0.15), phenylalanine (0.15)， 
lysine (0.23), tryptophan glycine (0.17), alanine (0.26), cystine (0.09)，valine 
(0.18), methionine (0.04)，histidine (0.07) and arginine (0.18). The amino acids 
most frequently found in the polypeptide are aspartic and glutamic acids. The 
polysaccharide portion is composed mainly of five different monosaccharides 
including glucose, galactose, mannose, xylose and arabinose. Their molar ratios 
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are 8.2 ： 1.5 ： 2.4 ： 2.4 ： 1.0. Besides these major monosaccharides, a small 
amount of rhamnose can also be found. The monosaccharides in PSP are mainly 
connected with l - > 4, l - > 2 and l - > 3 glucose; their glycoside linkages are 1-
Glc-4，l-Glc-2 and l-Glc-3, respectively, and the molar ratio is 3 : 2 : 1. Besides, 
there is also a small amount of 3, 1—4 and 6 galactose; l - > 3 and 6 
mannose; l - > 3 and 4 arabinose and the Cl-connected xylose. 
Freeze-dried samples of PSP are powdery and light reddish brown in 
color. PSP is insoluble in organic solvents such as methanol, pyridine, benzene, 
hexane and chloroform, but is highly soluble in water (25 °C). The pH of such a 
water solution of PSP is 6.6. PSP is stable to light and heat. There was no 
significant change in the saccharide peptide even when it was kept in water bath 
at 100 °C for 48 hours or irradiated for 30 hours under an ultraviolet lamp or 
maintained at high temperature (37 °C) and high humidity (99 % RH) for 3 
months. 
As in China, some ftingi belonging to Basidiomycetes have been used in 
Japan as folk remedies for the treatment of malignant neoplasms. Krestin (PSK), 
like PSP, is a protein-bound polysaccharide extracted from the cultured mycelia 
of Coriolus versicolor (Fr.) Quel. PSK exhibits a marked antineoplastic effect 
against both syngeneic and allogeneic tumors in experimental animals. When 
PSK is used in combinations with various anticancer agents (radiotherapy or 
chemotherapy), the antitumor activity of these agents is augmented and their side 
effects are prevented. PSK has no substantial effect on the immunological 
responsiveness of the host under normal conditions, but it has the ability to 
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restore immunological responsiveness to normal levels after it has been depressed 
by tumor-burden (Tsukagoshi et aL, 1981). Intraperitoneal administration ofPSK 
activates macrophages of the mononuclear-phagocytic system to release 
increased amounts of colony stimulating factor and interferon, which 
subsequently enhance the leukopoietic ftinctions. Inductions of neutrophil 
chemotactic factor (murine interleukin-8) and macrophage chemotactic factor 
(monocyte chemotactic and activating factor) have been reported to be the 
important triggers of the antitumor cascade reaction caused by PSK treatment in 
the double grafted tumor system (Sakagami et aL, 1991). Xu L.Z. of Shanghai 
Medical University (unpublished data) compared the anticancer effects of both 
PSP and PSK of Coriolus versicolor on four human tumor cell lines (SGC 7901， 
stomach cancer cell; SPC, human lung adenocarcinoma cell; SLY，human 
monocytic leukemia cell and Mei，human skin histiocytic lymphoma cell), and 
found that the anticancer effects of PSK were basically similar to those of PSP. 
Like PSP, PSK is a protein-bound polysaccharide (m.w. 9.4 x lO^ Da). PSK is 
insoluble in most organic solvents, but is highly soluble in water and has a pH of 
about 7. The amino acid constituents of PSK are similar to those of PSP, which 
consist predominantly of aspartic and glutamic acids. The polysaccharide portion 
of PSK comprises mainly glucose, with smaller amounts of mannose, fucose, 
xylose and galactose, all of these saccharides are also the predominant 
constituents of PSP. The structure of the main glycoside portion of PSK is (3-
glucan, and has a branched-structure including 1— 3, 4 and 6 bonds 
(Tsukagoshi et al, 1981), which is similar to the basic structural skeleton of PSP. 
Therefore, besides the anticancer effects, the physico-chemical properties of PSK 
and PSP are also similar. 
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The metabolic fates of PSK are better studied than those of PSP. When 
PSK was given orally to rats and rabbits, the compound was partially 
decomposed to small molecular products in the digestive tract. Within 2 hr after 
PSK were administered, small molecular products (m.w. < 500 Da) appeared, and 
thereafter, large molecular substances (m.w. > 10,000 Da) were detected in the 
digestive tract. In serum, the large molecular substances were observed even 
within 1 hr after PSK administration. These suggest that PSK is absorbed in its 
large molecular form and can exist in this state in the blood. No evidence of 
binding of PSK decomposed products to serum proteins is observed (Tsukagoshi 
et aL, 1981). Beside the normalization of host immunity towards tumors, PSK is 
also found to be effective for the recovery or enhancement of cellular immunity, 
as well as for the decrease of the symptoms and the prevention of relapse in 
patients with sarcoidosis, idiopathic nephrotic syndrome in children, and 
glomerulonephritis. Side effects such as bone marrow suppression, liver 
dysfunction (increase of GOT and GPT values), disturbance of digestive organs, 
renal dysfunction have not been observed from PSK treatment (Tsukagoshi et aL, 
1981). Since both PSP and PSK are protein-bound polysaccharides isolated from 
Coriolus versicolor, with high similarities in physico-chemical properties, it is 
reasonable to postulate that PSP may have similar toxicological and 
pharmacological effects as PSK. 
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1.2 Paracetamol (APAP) 
Paracetamol (Acetaminophen; 4-Acetyl-p-aminophenol; APAP) was first 
introduced into medicine by Von Mering in 1893, and is now one of the most 
commonly used non-narcotic analgesic-antipyretic agents. The structure of APAP 
is shown in Figure 1.01. The aminobenzene portion of APAP molecule confers 
its pharmacological activity; acetylation of the amino group and hydroxylation of 
the benzene ring in the para-position of APAP molecule reduces its toxicity as 
compared to its parent compound, aniline (Bowman and Rand, 1980). APAP is 
effective with low grade pain, but has little effect on visceral pain or pain due to 
wounding. The analgesic effect of APAP has not yet been fully elucidated. The 
drug probably acts by blocking prostaglandin biosynthesis by inhibiting the 
activities of cyclo-oxygenase which catalyses a bis-dioxygenation of arachidonic 
acid to form prostaglandin G2. Over-production of certain prostaglandins wil l 
lead to certain disorders like pain, fever and inflammation. The differential ability 
of APAP to produce analgesia and antipyresis without anti-inflammatory action 
may be due to the fact that APAP is only a weak inhibitor of cyclo-oxygenase 
from peripheral tissue, and it is more effective against cyclo-oxygenase derived 
from central-nervous system. In contrast to aspirin and other non-steroidal anti-
inflammatory drugs, APAP does not cause gastrointestinal bleeding, and there is 
no association of its use with the development ofReye's syndrome. 
Although APAP is remarkably safe at therapeutic doses, large overdose of 
the drug has been used in self-poisoning, first reported in Scotland in 1966 and 
followed by many similar reports in other countries (Prescott, 1983). Large 
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Figure 1.01. Structure of paracetamol (APAP) 
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overdoses of APAP cause dose-dependent centrilobular hepatic necrosis 
(Mitchell et al., 1973; Welty et al., 1993) and renal tubular necrosis (Siegers et 
al, 1989; Hu et aL, 1993) in experimental animals, including mice, rats, hamsters 
in vivo and in vitro (Mitchell et al, 1973; Hazelton et aL, 1986; James et al, 
1992; Nasseri-Sina et al., 1992; Hu et aL, 1993; Welty et al., 1993). Liver 
damage is associated with variable loss of hepatic enzymes, including 
cytochrome P450，and marked increases in the serum activities of enzymes such 
as aminotransferases and isocitric and sorbital dehydrogenases. The extent of 
histological hepatic necrosis in the rat and mice are closely related to elevation of 
serum transaminase activities (Mitchell et al, 1973; Hazelton et al., 1986; Welty 
et al., 1993). Intra- and inter- species differences in the susceptibility to APAP-
induced toxicity do exist. For example, APAP can cause hepatotoxicity in most 
rat strains, but nephrotoxicity primary in the Fischer 344 rat. Furthermore, 
hepatotoxicity of APAP has found to be age-, sex- and interspecies- dependent in 
laboratory animals. Mice and hamsters are especially sensitive to hepatotoxic 
effects of APAP (Vermeulen et al., 1992). Hamsters show much greater 
susceptibility to APAP toxicity than rats (Miller et al., 1993). 
Khedun et al. (1992) investigated the effect of therapeutic doses of APAP 
on liver function in the rat perftised liver, and found that when the rats were given 
0.02 g/kg APAP daily for ninety days the rate of glucose formation and glucose 
concentration were decreased, while lactate levels and lactateipyfuvate ratios 
were increased. Macro and micro vesicular fatty change was also present. This 
study demonstrated that, like acute overdose of APAP, chronic administration of 
therapeutic doses of APAP to rats might also adversely affect liver function. 
Furthermore, APAP can also cause a long-lasting 50 % reduction of the hepatic 
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ATP content, an irreversible loss of hepatic xanthine dehydrogenase activity, and 
a transient increase of the xanthine oxidase activity (Jaeschke, 1990). 
1.2.1 Metabolism of paracetamol (APAP) 
When APAP is administered into man or animals it wi l l be rapidly 
absorbed (Fischer et ai, 1981), and is extensively metabolized to glucuronide 
(APAP-G) and sulphate (APAP-S) conjugates (Howie et aL, 1977; Fischer et al., 
1981; Rashed and Nelson, 1989; Rustum，1989; Scott et al., 1990; Esteban et al.’ 
1991; Kim et aL, 1992; Scott et aL, 1990) as shown in Figure 1.02. Both 
glucuronidation and sulphation are low dose saturable processes, and sulphation 
has a higher affinity but a lower capacity than glucuronidation (Jollow et al, 
1973). Sulphate and glucuronide conjugates are rendered less lipid-soluble than 
APAP, and are more readily eliminated from the body. At low doses of APAP, 
the predominant metabolites in both serum and urine are APAP-S and APAP-G, 
but the fraction of the dose excreted as APAP-S in these fluids wi l l decrease 
substantially as the dose increases. On the other hand, APAP-G is excreted 
mainly into bile (Kim et aL, 1992). 
With overdosage of APAP such that both sulphation and glucuronidation 
are saturated, the excess amount of the drug wi l l be oxidized by cytochrome P450 
monooxygenase system to form a reactive metabolite, A^-acetyl-p-
benzoquinoneimine (NAPQI) (Jollow et aL, 1973; Mitchell et aL, 1973; Potter et 
al., 1973; Hoffmann et aL, 1985; Prasad et aL, 1990): NAPQI is electrophilic and 
wi l l react with nucleophilic sulphydryl of glutathione either by a non-enzymatic 
reaction or an enzymatic reaction via glutathione-«S-transferase 
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MERCAPTURIC ACID CELL DEATH 
Figure 1.02. Proposed biotransformation and bioactivation routes of paracetamol 
(APAP). Apart from detoxification via glucuronidation and sulphation, cytochrome 
P450-mediated bioactivation to ^-acetyl-p-benzoquinoneimine (NAPQI) is occurring. 
Detoxification of this reactive metabolite (with electrophilic and oxidant properties) is 
occurring via conjugation to glutathione (GSH). High dosages of APAP will deplete 
hepatic GSH and excess unconjugated NAPQI will bind to nucleophilic macromolecules 
within the hepatocyte and leads to cell death (adapted from Vermeulen et al，1992). 
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(GST) and made harmless (Mitchell et aL, 1973; Hazelton et aL, 1986; Svensson 
et aL, 1989; Dalhoff and Poulsen, 1993a; Davis et aL, 1993). In rat，the 
glutathione conjugate (APAP-GSH) is excreted in bile and reabsorbed as the 
cysteine conjugate after the loss of the glutamyl and glycyl residues in the 
intestine. The cysteine conjugate is then partially A^-acetylated in the kidney to 
yield the mercapturic acid conjugate (Prescott, 1983). However, high dosages of 
APAP deplete hepatic glutathione (Mitchell et aL, 1973; Liu et aL, 1993) and 
suppress the biosynthesis of glutathione. Therefore, NAPQI wil l remain 
unconjugated and cause damage to the hepatocytes. 
1.2.2 Mechanisms of paracetamol (APAP) toxicity 
Initially, covalent binding of the reactive metabolite of APAP to thiol 
groups of proteins, following a severe glutathione depletion, was thought to be 
responsible for the APAP-induced hepatotoxicity. However, more recent studies 
suggest that the APAP-induced hepatotoxicity is likely due to cellular stress 
(Adamson et aL, 1993), resulting in lipid peroxidation, protein thiol oxidation 
2+ 
and changes in the intracellular Ca homeostasis, all processes being potentially 
fatal to cells (Vermeulen et aL, 1992). 
1.2.2.1 Covalent binding hypothesis 
This hypothesis postulates that the toxicity of APAP is solely due to the 
covalent binding of NAPQI to vital nucleophilic macromolecules within the 
hepatocyte, and leads to their death (Vermeulen et al.’ 1992). This hypothesis is 
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supported by results from both in vivo and in vitro studies (Jollow et al.，1973; 
Pumford et al., 1989) which demonstrated that the hepatotoxic doses of APAP in 
mice were largely covalent-bound to the liver proteins in vivo (approximately one 
molecule bound per two molecules of protein in microsomes and cytoplasm). It 
was found that both covalent binding and hepatic necrosis were dose-dependent 
and proportional to each other, and the peak level of binding preceded the 
development of recognizable necrosis. The proportionality between the severity 
of hepatic necrosis and the formation of NAPQI was also observed using liver 
slices in vitro (Miller et al., 1993). Approximately 70 % of the covalent bound 
adduct is 3-cystein-iS-yl-4-hydroxyaniline, and cysteine residues represent the 
primary target sites for arylation by NAPQI. The highest concentration of 3-
cystein-6'-yl-4-hydroxyaniline protein adducts was located in plasma membranes 
and mitochondria. Adducts in the cytosol increased to the maximum level at 2 hr 
and then decreased to 30 % of the maximum level by 8 hr after APAP was 
administered. Concomitant with the decrease in adducts in the cytosol 3-cystein-
iS-yl-4-hydroxyaniline protein adducts appeared in serum, and their levels 
paralleled increases in serum aminotransferases (Pumford et al., 1989). Proteins 
which are rich in free thiols, including GST and Ca^^-dependent ATPase, are 
especially vulnerable to damage by NAPQI (Hoffmann et al., 1985). Apart from 
covalent binding to cytosolic proteins and glutathione, covalent binding to 
mitochondrial glutathione and proteins may also be an important event in the 
induction of cytotoxicity of APAP (Burcham and Harman, 1990). The loss of 
mitochondrial respiratory ftinction is accompanied by a decrease in ATP levels 
and ATP/ADP ratios in the cytosolic compartment, and is preceded by a loss of 
GSH in both the cytosol and mitochondria. 
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However, several recent in vitro and in vivo studies claimed a dissociation 
of the covalent binding process from cell death induced by APAP. Incubation of 
rat hepatocytes with both APAP and cysteine, a precursor of glutathione, resulted 
in both protection and increased glutathione synthesis, but not increased APAP-
GSH synthesis (Dalhoff and Poulsen, 1993b). The phenomenon indicated that the 
hepatoprotection effect of cysteine on APAP toxicity is primary due to a 
stimulation of glutathione-mediated reduction of NAPQI back to APAP, rather 
than the direct conjugation of glutathione to NAPQI. The oxidative rather than 
the electrophilic properties of NAPQI is more significant in inducing necrosis to 
hepatocytes. 3-Hydroxyacetanilide, an analog of APAP, can produce levels of 
covalently bound radiolabel that is similar to those observed after an equimolar, 
hepatotoxic dose of [ G - t f ] APAP, but it does not induce necrosis in liver of 
hamsters (Roberts et al.’ 1990). The above results illustrated a dissociation of 
covalent binding from hepatic necrosis, and the levels of covalently bound 
xenobiotic metabolites cannot be used as absolute predictors of cytotoxic 
potential. Covalent binding by itself, therefore, is apparently important but is not 
the only mechanism by which APAP can induce toxicity. 
1.2.2.2 Oxidative Stress Hypothesis 
More recent studies point to an imperative role of oxidative stress as an 
additional or even alternative process accounting for the hepatocellular toxicity of 
2+ 
APAP. Oxidative stress has been shown to result in lipid peroxidation and Ca 
dyshomeostasis. Incubation of hepatocytes with APAP produced a time-
dependent loss of cell viability which was preceded by depletion of glutathione 
and an increase in oxidized glutathione (GSSG) formation (Adamson et al, 
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1993). Increasing the susceptibility of hepatocytes to an oxidative stress increases 
both the formation of GSSG and cell killing produced by APAP. Conversely, 
decreasing their susceptibility to an oxidative stress decreases GSSG formation 
and cell injury. The results suggested that APAP toxicity involves oxidative 
processes that occurs early in the poisoning process, and is a major factor 
contributing to injury in these cells. 
a. Disturbance of the calcium homeostasis 
I 
Normally, the cytosolic Ca concentration in hepatocytes, which is 
extremely low (10"^  M) compares to the extracellular environment (10"^  M)，is 
maintained by active compartmentation in the mitochondria and endoplasmic 
2+ 
reticulum, by protein binding, and by active extrusion of Ca through the plasma 
membrane (Vermeulen et al., 1992) as shown in Figure 1.03. Mitochondria are 
thought to contain between 65 % and 80 % of the total cell Ca^ "^  (Reed and Fariss, 
1984). The release of Ca^ "^  ions from the mitochondria Ca^ pool is most probably 
regulated by the NADPH/NADP+ redox level, though sulphydryl groups of 
membrane-bound proteins may also be important in modulating mitochondrial 
Ca2+ fluxes. The active transport of Ca^ ions into the endoplasmic reticulum and 
plasma membrane is mediated by Ca ATPases, which have been shown to 
depend on free sulphydryl groups for activity (Vermeulen et al., 1992). The 
intracellular Ca^^  homeostasis is susceptible to depletion of glutathione level in 
cells, as glutathione plays an essential role in the regulation of the cellular protein 
thiol-disulphide status. Upon depletion of cellular glutathione, a loss (by arylation 
and oxidation) of critical protein thiol groups may occur causing a 
14 
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Figure 1.03. Ca^ "^  compartmentation in the hepatocyte. The low cytosolic 
concentration 
(10%) 
is maintained by active compartmentation in the 
mitochondria and endoplasmic reticulum, by protein binding, and active 
extmsion of Ca2+ through the plasma membrane (adapted from Vermeulen et 
ah 1992). 
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disruption of the intracellular Ca homeostasis which results in an increase of the 
cytosolic Ca2+ level. 
2+ • 
Paracetamol overdose in mice causes accumulation of Ca in both cytosol 
and nucleus (Ray et al., 1993). An elevated cytosolic Ca^^ level resulted in 
saturation of Ca^ "^  binding sites on cytoskeletal proteins leading to extensive 
membrane blebbing, the stimulation of Ca '^^ -dependent phospholipase leading to 
• • 2 + 
membrane digestion and arachidonate release, the activation of Ca -dependent 
proteases with destruction of critical yet-unidentified proteins, and the loss of 
mitochondrial ATP production with a decline in ion pumping and pH regulation. 
The elevated Ca^^ level in nucleus induces DNA fragmentation (Ray et al, 
1993). Pretreatment with chlorpromazine (a Ca - calmodulin antagonist) or 
verapamil (a Ca^^ channel blocker) prevented the increases in nuclear Ca^^ and 
DNA fragmentation, and nearly abolished the biochemical evidence of toxic cell 
death (Ray al, 1993). 
b. Lipid peroxidation 
Lipid peroxidation is a free radical-initiated process which, upon 
peroxidation of unsaturated membrane lipids, may lead to loss of cellular 
integrity and viability. This mechanism has been shown to be involved in the 
hepatotoxic action of halomethanes, including tetrachloromethane (Muriel and 
Mourelle, 1990), and other redox cycling compounds. In the case of APAP 
intoxication wil l result in an increase in lipid peroxidation, as indicated by 
elevated plasma level of malondialdehyde which is a product of lipid 
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peroxidation (Muriel et aL, 1992; Yamada et al., 1993). However, lipid 
peroxidation is not the primary mechanism by which APAP exerts its hepatotoxic 
action. Lipid peroxidation, in the case of APAP overdosage, may be the result 
rather than the cause of necrosis (Vermeulen et al., 1992). It still remains to be 
established how antioxidants like allopurinol (Jaeschke, 1990), silymarin (Muriel 
et aL, 1992) and gomisin A (Yamada et al, 1993), which are expected only to 
inhibit lipid peroxidation, protect against the hepatotoxicity of APAP. 
In addition to covalent binding of NAPQI to vital cellular proteins and 
oxidative stress, other processes such as impairment of energy metabolism, 
inhibition of electron transport chain and fall in cellular ATP level (Burcham and 
Harman, 1990) may also contribute to APAP toxicity (Vermeulen et al., 1992). 
These mechanisms, however, are less studied as compare to the covalent binding 
and oxidative hypotheses. 
1.2.3 Factors influencing the hepatotoxicity of paracetamol (APAP) 
Paracetamol toxicity depends on factors which influence the balance 
between the rate of formation of NAPQI and the maximum rate of glutathione 
synthesis. The rate of NAPQI formation depends on the dose, rate of absorption, 
uptake by the liver, capacity for glucuronide and sulphate conjugation and 
microsomal enzyme activity; while the synthesis of glutathione is primarily rate-
limited by the supply of its precursor, cysteine (Tateishi and Higashi, 1978). 
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a. Drug metabolism 
Taking into consideration the mechanisms of the bioactivation and 
inactivation of APAP that have been discussed in section 1.2.1, APAP-induced 
hepatotoxicity may be interfered by altering the biochemical processes involved 
in the metabolism of APAP, as well as the ways in which it causes damages to 
hepatocytes. 
L Interference with glutathione and glutathione-dependent enzymes ‘ 
Prevention of glutathione depletion and stimulation of GST activity 
probably represent the most efficient methods of direct protection against the 
chemically reactive metabolite of APAP (Vermeulen et al., 1992). Several 
methods which aimed at the repletion of glutathione by stimulation of its 
synthesis have been successftilly used in the protection against APAP-induced 
hepatotoxicity in animal or man. L-cysteine (Miners et al” 1984; Dalhoff and 
Poulsen, 1993c) and L-cysteine precursors, such as A^-acetyl-L-cysteine (Miners 
et al., 1984; Hazelton et al., 1986), methionine (Miners et al, 1984), L-2-
oxothiazolidine-4-carboxylate (Hazelton et al., 1986), L-2-methylthiazolidine-4-
carboxylate (Hazelton et al., 1986) have been shown to protect against APAP 
toxicity. Incorporation of L-cysteine into glutathione intracellularly, and not the 
liberation of sulphydryl groups appears to be important, since D-cysteine 
prodrugs were found to be totally ineffective as protecting agents (Hazelton et al.’ 
1986). Conversely, depletion of hepatic glutathione may potentiate APAP-
hepatotoxicity. Buthionine sulphoximine, a specific inhibitor of y-
glutamylcysteine synthetase in glutathione synthesis, depletes hepatic glutathione 
content and potentiates APAP hepatotoxicity (Miners et al, 1984; Dalhoff and 
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Poulsen, 1993b,c). Phenylpropanolamine, an adrenergic agonist, decreased 
glutathione by increasing the sinusoidal efflux of glutathione from the liver 
and/or decreasing in glutathione synthesis, potentiates APAP toxicity (James et 
al., 1992). 
Conjugation of NAPQI to glutathione is apparently more effective than 
thiol-mediated reduction of NAPQI back to APAP (Vermeulen et al., 1992). In 
line with this hypothesis, pretreatment of rats with sodium selenite and D-
limonene efficiently protected against APAP hepatotoxicity (Reicks and 
Crankshaw, 1993). Both are due to the effects of significant induction of GST 
activity. 
iL Interference with other biochemical mechanisms 
Inhibition of the formation of NAPQI, notably by inhibiting cytochrome 
P450 by cobaltous chloride (Madhu et aL, 1988), dimethylsulphoxide (Jeffery et 
aL, 1988; Madhu et al., 1988), dimethylsulphide (Jeffery et al., 1988)，cimetidine 
(Dalhoff and Poulsen, 1993a), cysteamine (Madhu et aL, 1988; Miners et al., 
1984), and amiodarone (Svensson and Chong, 1989) have been successfully used 
to prevent APAP-induced hepatotoxicity. Ethanol plays a dual role in the 
intoxication of APAP. Chronic administration of ethanol increases the acute 
toxicity of APAP, while acute administration of ethanol decreases the toxicity of 
APAP presumably by inhibiting metabolic activation of the drug (Prasad et al., 
1990). 
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Antioxidants, like allopurinol (Jaeschke, 1990), silymarin (Muriel et al., 
1992) and gomisin A (Yamada et aL, 1993) have been shown to be effective in 
protecting against cytotoxicity or, more specifically, against lipid peroxidation 
induced by APAP. Oleanolic acid reduces hepatotoxicity of APAP by enhancing 
hepatic UDP-glucuronosyltransferases (UDPGTs, enzymes catalyse 
glucuronidation) activity toward APAP (Liu et al., 1993); whereas synthetic 
glucocorticoids, like prednisone and prednisolone, are known to inhibit APAP 
glucuronidation (Harvey et aL, 1993). Ca^'^-calmodulin antagonist 
chlorpromazine and the Ca channel blocker verapamil prevent APAP-induced 
hepatic necrosis by inhibiting Ca deregulation and DNA damage (Ray et al., 
1993). 
iii. Diet and Nutrition 
Factors such as fasting, diet and nutritional state may influence drug 
metabolism and hepatic glutathione content. It is well documented that hepatic 
glutathione is reduced in rats fed low protein or yeast diets, and their 
susceptibility to the lethal and hepatotoxic effects of APAP is greatly enhanced. 
Cytochrome P450 levels are slightly, but significantly, increased in the fasted 
rats. However, cytochrome P450 levels are significantly lower in the liver of the 
animals ingesting sucrose, both when compare to animals receiving the 
commercial diet and to fasted animals (Martinelli et al., 1993). Cholestyramine is 
a potent antidote in the treatment of APAP poisoning, as explained by almost 
complete interruption of the enterohepatic circulation of APAP and conjugates 
undergoing biliary excretion. 
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iv. Age, Sexes and Obesity 
It has been postulated that aging is associated with a general deficiency of 
glutathione (Vermeulen et al, 1992). There was no age-related differences in the 
glutathione baseline in mice, and the deficiency of glutathione in liver is not 
apparent until about 29 months of age. Fasting induces an age-dependent 
reduction in hepatic glutathione, culminating in a 4-fold decrease during 
maturation and a 5-fold decrease during aging compared to young animals (Vogt 
and Richie, 1993). Liver weight also declines with age, decreasing total liver 
GSH content by 24 % in young (6 months), 44 % in mature (12 months), and 
56 % in old (24 months) mice. These aging changes are probably due to 
decreased glutathione turnover resulting from impaired biosynthesis. The 
depleted glutathione levels during aging wil l affect the efficiency of conjugation 
of various xenobiotics, including NAPQI in the metabolism of APAP. 
Hu et al. (1993) reported that a significant sex-related difference was 
observed in the NADPH-dependent formation of NAPQI during the metabolic 
activation of APAP in mouse kidneys. The enzyme activity of P450 2E1 in male 
mouse kidney is about 35- to 50- fold higher than that in the females. This sex-
related difference in P450 2E1 enzyme activity wil l result in different degree of 
susceptibility to APAP toxicity in different sexes. 
Chaudhary et al. (1993) found that genetically obese Zucker rats had a 
higher glucuronidation capacity as evidenced by a higher formation clearance of 
APAP-G and greater UDPGT activity toward APAP compared with lean 
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controls. Furthermore, the obese Zucker rats possessed a higher total hepatic 
glutathione content due a greater liver weight. Since glucuronidation is a main 
process in the clearance of APAP, the obese Zucker rats have a lower 
susceptibility to APAP toxicity than the lean rats. 
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1.3 Aim of the present study 
As described in section 1.1, PSP is a protein-bound polysaccharide 
extracted from a basidiomycete Coriolus versicolor, and has been used recently 
in China as an immunomodulator and an anticarcinogen in both experimental 
studies and clinical trials. Although it has been proposed that the 
immunomodulatory actions of PSP is T-cell mediated (Yang et al, 1991)，the 
exact mechanisms remain controversial. In various ways it has been established 
that glutathione and other sulphydryl status play important roles in prostaglandin 
and leukotriene metabolism, immune function and cell proliferation, and liver is 
the major organ for synthesis and export of glutathione into systemic circulation 
(Bray and Taylor, 1993). As a proposed immunomodulator, it would be of great 
interests to investigate whether or not the administration of PSP would affect 
hepatic glutathione and its status in vivo. 
PSK (a similar compound extracted from C. versicolor) has been found to 
be immunomodulatory and cytoprotective (Tsukagoshi et al., 1981). As PSP and 
PSK have similar physico-chemical and pharmacological properties, it has been 
proposed that PSP may also have cytoprotective effects to certain extents. In the 
present study, paracetamol (APAP) is chosen as the model toxin for the 
evaluation of the potential cytoprotective effects of PSP because the drug is 
mainly metabolized and causes damages in liver (section 1.2.2). Liver, which 
receives 25 % of the cardiac output, has a primary function of receipt and 
processing of chemicals absorbed in the gastrointestinal tract. The liver, 
therefore, is important in biotransformation of xenobiotics, and plays a key role 
in toxicity and carcinogenicity. The APAP model is a well studied and 
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understood model of drug-induced toxicity, and would be particularly relevant to 
the proposed use of PSP as an adjuvant in cancer chemotherapy when multiple 
drugs are administered, given that the metabolism and toxicity of APAP may be 
affected by a large number of factors. Furthermore, since the biotransformation 
of APAP involves both phase I (cytochrome P450 oxidation) and phase I I 
(sulphation, glucuronidation and glutathione conjugation) reactions, the potential 
drug-drug interactions of PSP on the metabolism and toxicity of APAP wil l 




Studies on the effects of polysaccharide-peptide (PSP) on 
paracetamol (APAP) - hepatotoxicity and glutathione levels 
2.1 Introduction 
Paracetamol (APAP) is one of the safest over-the-counter antipyretic-
analgesic drugs available which can produce a fulminating hepatic necrosis in 
overdose. The toxicity of paracetamol is metabolically based, due to the 
formation of a chemically reactive metabolite as previously discussed (section 
1.2.1). This electrophile binds covalently to macromolecules and causes 
glutathione depletion, oxidative stress and changes in the calcium and/or thiol 
status (section 1.2.2). The importance of the cellular glutathione status in APAP 
toxicity have been well demonstrated in which measures that deplete glutathione 
or inhibit its redox cycling wil l potentiate toxicity, whereas compounds that 
sustain cellular glutathione metabolism, such as the clinically used iV-acetyl-L-
cysteine, wil l protect against toxicity (section 1.2.3). The maintenance of hepatic 
glutathione levels is crucial to assure an adequate defense against covalent 
binding of NAPQI to important macromolecules and results in cellular necrosis. 
The availability of glutathione is determined by its steady state concentration, 
which depends on the rate of de novo synthesis, and the rate of. glutathione 
utilization. The synthesis of glutathione is a two-step process involving the 
constituent amino acids glutamine，cysteine and glycine, and the enzymes y-
glutamylcysteine synthetase and glutathione synthetase. The synthesis of 
glutathione is regulated by feedback inhibition of y-glutamylcysteine synthetase 
by glutathione. Reduction of oxidized glutathione (GSSG) by GSSG reductase 
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represents another source of glutathione. Homeostasis of hepatic glutathione pool 
under normal conditions is maintained by continuous turnover of glutathione, 
involving synthesis and degradation. Degradation is accomplished by the efflux 
of reduced glutathione (GSH) across sinusoidal and canalicular membranes, 
consumption by conjugation reactions, oxidation to GSSG and enzymatic 
breakdown (Lauterburg et aL, 1984). Depletion by conjugation reactions during 
stressed conditions can cause rapid synthesis of glutathione, and the increased 
demand for cysteine can be met by the highly responsive cystathionine pathway 
(Figure 2.01; Reed and Beatty, 1978). Basically, the cystathionine pathway 
involves the conversion of methionine to homocysteine, which can be 
irreversibly metabolized to cystathioine, yielding cysteine. Alternatively, 
homocysteine can be remethylated in either of two methionine salvage pathways. 
These pathways involve reactions catalyzed by either N^-methyltetrahydrofolate-
homocysteine methyltransferase or the betaine-homocysteine methyltransferase. 
The regulation of methionine metabolism in mammalian liver is probably 
dependent on the enzymes that utilize homocysteine. It has been suggested that 
the concentration of AS-adenosylmethionine is particular important in determining 
the activities of enzymes utilizing homocysteine as a substrate (Reicks and 
Hathcock, 1988). The 5-adenosylmethionine concentration functions as functions 
as a ‘ switch ’ to turn off remethylation at high dietary protein, or excess 
methionine, concentrations by activating cystathionase and, therefore, cysteine 
synthesis. At low protein or methionine-deficient concentrations, S-
adenosylmethionine concentrations are low; cystathionine synthesis is turned off 
and homocysteine remethylation is turned on to regenerate methionine. The level 
of cysteine available for incorporation into glutathione is the rate-limiting factor 
in glutathione biosynthesis (Krebs et al., 1978). The hepatic cysteine 
concentration is dependent on the activity of the cystathionine 
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Figure 2.01. Cystathione pathway. The reactions include the conversion of 
methionine to homocysteine, which can be irreversibly metabolised to 
cystathionine, yielding cysteine. The homocysteine can also be remethylated in 
either of two methionine salvage pathways. 1: 5-adenosylmethionine synthetase 
2: methyl transferase 3: 5-adenosylhomocysteine hydrolase 4: cystathionine 
synthase 5: y-cystalhionase 6: cysteine oxidases 7: N^-methyltetrahydrofolate-
homocysteine transmethylase 8: homocysteine-betaine transmethylase (adapted 
from Reicks and Hathcock, 1988). 
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pathway, dietary intake and endogenous protein turnover. The extent of 
glutathione resynthesis after challenge by toxic compounds is dependent on many 
complex, interactive factors, including the time of day and the time the last meal 
was eaten, the dietary amino acid intake and the requirements of protein synthesis 
for amino acids and of methylation reactions for methionine (Reicks and 
Hathcock, 1988). APAP is conjugated with GSH following activation by the 
cytochrome P450 monooxygenase system in liver microsomes. GSH conjugation 
is mediated by a family of enzymes, the glutathione-iS-transferases. The y-
glutamyl group of the glutathione conjugate is removed and the glycyl residue is 
eliminated by hydrolysis. The remaining iS-cysteine conjugate is then acetylated 
by an A^-acetyltransferase enzyme located in the endoplasmic reticulum. 
Activation and GSH conjugation occur primarily in the liver and A^-acetyl-
cysteine conjugate formation occurs primarily in the kidney (Figure 2.02). 
In this study, the effect of PSP on APAP-induced hepatotoxicity was 
investigated in the rat and in the mouse. In addition, the effect of PSP on the 
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Figure 2.02. Formation of glutathione conjugate and then mercapturic 
acid (acetylcysteine) conjugate from an epoxide (adapted from Bowman and 
Rand, 1980). . 
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2.2 Materials and methods 
2.2.1 Chemicals and Reagents 
4-Acetyl-p-aminophenol (APAP), a-ketoglutarate, p-nicotinamide 
adenine dinucleotide phosphate (reduced, tetrasodium salt, NADPH), 5,5'-
dithiobis-(2-nitrobenzoic acid) (DTNB), 2,4-dintrophenylhydrazine (DNP), DL-
alanine, ethylenediaminetetraacetic acid (EDTA)，glutathione (reduced, GSH), 
glutathione reductase (Type III), glyoxalase I (Grade IV)，heparin (sodium salt, 
Grade II), L-aspartate, methylglyoxal (40 % aqueous solution), 3-[N-morpholino] 
propanesulphonic acid (MOPS)" and Tween 80 were purchased from Sigma 
Chemical Co. (St. Louis, Mo., U.S.A.). Di-sodium hydrogen phosphate 
dehydrate, perchloric acid, potassium dihydrogen phosphate, potassium 
hydroxide and sodium hydroxide were supplied by E. Merck (Darmstadt, 
Germany). Sodium chloride was purchased from BDH Limited (Poole, England). 
Polysaccharide-peptide (PSP) was kindly donated by Winsor Health Products 
Limited (Hong Kong). 
2.2.2 Animals 
Male Sprague-Dawley rats (250-350 g) and C57 mice (25-30 g), obtained 
from Animal House (The Chinese University of Hong Kong, Hong Kong), were 
housed in groups of 5 in stainless steel cages in a temperature- and humidity-
controlled animal facility with a 12-hr light-dark cycle, and allowed rodent chow 
(PMI Feeds Inc., St. Louis, Mo., U.S.A.) and water ad libitum. Al l the rats and 
mice were acclimated for at least 1 week before use. 
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2.2.3 Study on the effects of polysaccharide-peptide (PSP) on 
paracetamol (APAP) - hepatotoxicity in the rat and in 
the mouse 
Male Sprague-Dawley rats (250-350 g) were fasted overnight, and were 
divided into 3 different groups. APAP (1.5 g/kg, 75 mg/ml in 20 % Tween 80) 
was administered orally to rats of both Groups 2 and 3 (n = 20 in each group). 
PSP (300 mg/kg, 30 mg/ml in saline) was administered intraperitoneally to Group 
3 rats 6 hr after the administration of APAP. Group 2 rats were under identical 
treatments as rats of Group 3 but received only saline (10 ml/kg). Rodent chow 
was resumed immediately after the drug administration. The rats were sacrificed 
for blood by heart puncture after 18 hr. Rats in Group 1 (n = 10) received/the 
same treatments as those in the other groups, except that only 20 % Tween 80 (20 
ml/kg) and saline (10 ml/kg) were given. 
Male C57 mice (25-30 g) were divided into 3 different groups; Groups 2 
and 3 mice (each group n = 4) were given APAP intraperitoneally (300 mg/kg, 30 
mg/ml in saline), and PSP (200 mg/kg, 20 mg/ml in saline) was administered ‘ 
intraperitoneally to Group 3 mice only 6 hr after APAP was administered. Mice 
of Group 2 were under identical treatments as those of Group 3 except that only 
saline (10 mg/kg) was given. Group 1 mice (n = 5) were under the same 
treatments as those in the other groups but saline (10 mg/kg) was given instead of 
APAP and PSP. Al l the mice were sacrificed and blood was obtained by heart 
puncture 18 hr after PSP or saline was administered. 
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2.2.3.1 Determinations of glutamate-pyruvate transaminase (GPT) and 
glutamate-oxaloacetate transaminase (GOT) levels in plasma 
Blood samples were collected into heparinized microcentrifuge tubes, and 
centrifiiged at 2,000 x g for 15 min (MSE microcentrifuge, England) to obtain 
the plasma samples. The glutamate-pyruvate transaminase (GPT) activity in 
plasma was determined (Reitman and Frankel, 1957). Briefly, 0.1 ml plasma 
sample was mixed with 0.5 ml pre-incubated (37 °C) GPT substrate solution (a-
ketoglutarate, 2 mM/L; DL-alanine, 200 mM/L in 0.1 M phosphate buffer, pH 
7.4 ) in test tube. The mixture was then incubated in a water bath (SWB 20, 
Haake, Germany) at 37 °C for 30 min. 0.5 ml of 1 mM 2,4-
dinitrophenylhydrazine (DNP) was added and the mixture was placed in room 
temperature for 30 min. 5 ml of 0.4 N NaOH was then added and waited for 10 
min for color development. Absorbance of the mixture was measured at 505 nm 
I 
I 
(220S spectrophotometer, Hitachi, Japan). To determine glutamate-oxaloacetate ‘ 
transaminase (GOT) activity in the plasma, a similar procedure as those of GPT 
determination was used, except that the plasma sample (0.1 ml) was mixed with 
0.5 ml of GOT substrate solution (a-ketoglutarate, 2 mM/L; L-aspartate, 200 
mM/L in 0.1 M phosphate buffer, pH 7.4) and incubated at 37 °C for 60 min. 
I 
Standard curves of GPT (Figure 2.03) and GOT (Figure 2.04) were prepared as 
shown in Table 2.01 and Table 2.02, respectively. GPT and GOT levels in the 
plasma samples were determined by referring to their respective standard curves. 
3 2 
0.45 
0.40 - y / ^ ( 
i / ‘； 
VD - / 
® 0.35 一 y / 
« / ! 
i / I 
I 0.30 一 / 
^ / 
^ / : 
0.25 - / • I 
/ ‘ 
0.20 J , , , , , 
0 50 100 150 200 250 
Plasma GPT activity ( SF units/ml) 









0 0.30 - / 
1 / 
0.25 一 / 
0.20 4 , , 1 1 
0 50 100 150 200 
Plasma GOT activity (SF units/ml) 
Figure 2.04. Standard curve for glutamate-oxaloacetate transaminase (GOT) 






































































































































































































































































































































2.2.4 Studies to investigate the acute and sub-chronic effects of 
polysaccharide-peptide (PSP) on glutathione in rats 
To investigate the interactions of APAP and PSP on hepatic glutathione, 
male Sprague-Dawley rats (250-350 g) were divided into 3 different groups (each 
group n = 5) and were under identical treatments as those for studying the effects 
of PSP on APAP-hepatotoxicity (section 2.2.3). Al l the rats were sacrificed for 
liver by cervical dislocation 18 hr after PSP or saline was administered. 
\ 
4 
The effects of PSP on glutathione status were studied by giving PSP (300 
mg/kg, 30 mg/ml in saline) intraperitoneally to three different groups of rat (each ； 
group n = 10). The control group (n = 6) was administered saline only (10 ml/kg). | 
The three groups of rat given PSP were sacrificed for blood by heart puncture at i 
6, 12, and 18 hr after the PSP administrations; liver samples were also dissected ‘ 
out and glutathione in blood and liver were determined immediately. 
In sub-chronic studies, PSP at doses of 100，200, 300，and 400 mg/kg/day 
(20 mg/ml in saline) was administered intraperitoneally to rats (each group n = 
10) for 7 days. The last dose of PSP was administered 6 hr before the rats were 
sacrificed. The control group (n = 18) was given the same treatment as the 
experimental groups, except that only saline (20 ml/kg) was administered. The 
rats were sacrificed for livers by cervical dislocation, and hepatic glutathione was 
determined immediately. Al l the rats were sacrificed before noon to avoid 
interference from diurnal variations of glutathione content in liver (Reed and 
Terris，1984; Bray and Taylor, 1993). 
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2.2.4.1 Determinations of tissue glutathione 
To determine glutathione concentration in blood, 1.5 ml of blood sample 
was mixed with 1.5 ml of ice-cold perchloric acid (2 M) containing 4 mM 
ethylenediaminetetraacetic acid (EDTA). In determining hepatic glutathione 
concentration, an aliquot (0.3-0.5 g) of the liver was homogenized with motor-
driven glass-Teflon homogenizer in ice-cold 1 M perchloric acid (3 ml) 
containing 2 mM EDTA. The blood mixture and the liver homogenate were then 
centrifuged (2,000 x g) for 15 min at 4。C (centrifuge SCR 18B, Hitachi, Japan) 
to obtain a clear supernatant. An aliquot (0.3 ml) of the acidic supernatant was 
neutralized with 0.3 ml of 0.85 M potassium hydroxide containing 0.3 M of 3-[N-
morpholino] propanesulphonic acid (MOPS). The mixture was then centrifiiged 
for 30 sec at 2,000 x g (MSB microcentrifuge, England). The sample was assayed 
for total glutathione (GSH + GSSG) and reduced glutathione (GSH) immediately 
after neutralization, by methods described by Akerboom and Sies (1981). In 
brief, the assay for total glutathione (GSH + GSSG) was started by mixing 20 
neutralized sample with 100 |il p-nicotinamide adenine dinucleotide phosphate 
(reduced, NADPH; 5.2 mM), 40 |il 5,5'-dithiobis-(2-nitrobenzoic acid) (DTNB; 
3.8 mM) and 1800 phosphate buffer (0.1 M with 1 mM EDTA, pH 7.0). The 
solutions were mixed in a cuvette at 25 °C and the absorbance was continuously 
monitored at 412 nm (spectrophotometer 220S, Hitachi, Japan) for 30 sec after 
the addition of 40 |il glutathione reductase (3.4 units/ml). The initial rate of the 
reaction was measured, and total glutathione (GSH + GSSG) content in the 
sample was determined by reference to the linear ranges (0.1-1 mM) of a 


















































































































































To measure reduced glutathione (GSH) level in blood and liver, 100 |il of 
the neutralized sample was mixed with 40 |il glyoxalase I (18 units/ml) and 1.84 
ml phosphate buffer (0.05 M, pH 6.6) in a cuvette at room temperature. The 
absorbance was measured at 240 nm. The reaction was started by adding 20 \l\ 
methylglyoxal (110 mM)，and incubated at room temperature for 10 min. 
Absorbance was measured again at the end of incubation. Another 20 |il 
methylglyoxal was added and the absorbance of the final mixture was measured. 
2.2.5 Statistic analysis 
An unpaired Student's t test was used for all comparisons between the 
treated and control groups. In all cases, the criterion for statistical significance 
was P < 0.05. Data are presented as the mean 士 S.E. 
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2.3 Results 
2.3.1 The effects of polysaccharide-peptide (PSP) on paracetamol 
(APAP) - induced hepatotoxicity 
Oral administration of APAP (1.5 g/kg) into rats resulted in 4-fold and 8-
fold elevations of plasma levels of glutamate-pyruvate transaminase (GPT) and 
glutamate-oxaloacetate transaminase (GOT), respectively, as shown in Figures 
2.05 and 2.06. The plasma GPT and GOT in the control rats were 105 ± 4 and 54 
± 6 SF units/ml, respectively, while the toxic dose of APAP significantly 
increased the respective plasma enzyme values to 511 ± 71 and 462 士 63 SF 
units/ml. This indicated substantial damages to liver were caused by the dose of 
APAP used. As shown in Figures 2.05 and 2.06, intraperitoneal administration of 
PSP (300 mg/kg) reduced the extent of APAP-induced elevations of both GPT 
(by 63 o/o) and GOT (by 67 %), respectively. The plasma values of GPT and GOT 
in the PSP-treated group were found to be 187 士 58 and 152 ± 48 SF units/ml, 
respectively. These were significantly lower than rats which received only APAP, 
but were still slightly higher than the normal controls. 
In the mouse, intraperitoneal administration of APAP (300 mg/kg) 
increased plasma level of GPT from 53 ± 5 SF units/ml in the controls to 28480 士 
2342 SF units/ml, as shown in Figure 2.07. The elevation of plasma GPT level 
(by 535 folds) indicated that the dose of APAP was hepatotoxic to the mice. The 
co-administration of PSP (200 mg/kg, i.p.) significantly reduced the elevation of 
plasma GPT level by 29 % in APAP-treated mice, but was still higher than the 
41 
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Figure 2.05. Effects of PSP on plasma glutamate-pyruvate transaminase ( GPT ) activities 
in rats 24 hr after APAP-treatment. Rats were pretreated with APAP ( 1.5 g/kg, p.o. ) or 





Control APAP APAP + PSP 
Figure 2.06. Effects of PSP on plasma glutamate-oxaloacetate transaminase ( GOT ) 
activities in rats 24 hr after APAP-treatment. Rats were pretreated with APAP ( 1.5 g/kg, 
P.O.) or 20 % Tween 80 in saline, followed by PSP ( 300 mg/kg, i.p.) 6 hr later. Values 
represent mean 士 S.E. of ten to twenty rats. *** Indicates significant difference from 
controls at P < 0.001; + + indicates significant difference from APAP group at P < 0.01. 
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Figure 2.07. Effects of PSP on plasma glutamate-pyruvate transaminase ( GPT ) activities 
in mice 24 hr after APAP-treatment. Mice were pretreated with APAP ( 300 mg/kg, i.p.)， 
followed by PSP ( 200 mg/kg, i.p. ) 6 hr later. Values represent mean 土 S.E. of four to 
five rats. *** Indicates significant difference from controls at P < 0.001; ++ indicates 
significant difference from APAP group at P < 0.01. 
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normal controls. Thus, PSP significantly decreased the elevations of plasma 
transaminase levels induced by APAP in Sprague-Dawley rats and C57 mice. 
2.3.2 The acute and sub-chronic effects of polysaccharide-peptide 
(PSP) on glutathione in rats 
2.3.2.1 Acute effects of polysaccharide-peptide (PSP) on glutathione 
Oral administration of APAP (1.5 g/kg) depleted hepatic total glutathione 
(GSH + GSSG) by 50 % from 7.27 土 0.50 |imol/g in control rats to 3.64 士 0.72 
fimol/g 24 hr after APAP was administered, as shown in Figure 2.08. Co-
administration of PSP (300 mg/kg, i.p.) increased the depleted level of hepatic 
total glutathione (GSH + GSSG) induced by APAP but did not attain a 
statistically significant level, such that the total glutathione (GSH + GSSG) level 
was still 45 % lower than controls (Figure 2.08). A similar observation was found 
in PSP effects on hepatic reduced glutathione (GSH) level (Figure 2.09); APAP 
(1.5 g/kg, P.O.) depleted hepatic GSH by 52 % from normal rats 5.11 士 0.36 
|imol/g to 2.47 土 0.54 ^mol/g 24 hr after APAP was administered, and co-
administration of PSP (300 mg/kg, i.p.) did not replenish significantly the APAP-
induced depletion of hepatic GSH (remained at 37 % of controls). As shown in 
Figure 2.10, APAP (1.5 g/kg, p.o.) decreased hepatic level of oxidized 
glutathione (GSSG) by 46 % from control level 1.08 士 0.09 ^imol/g to 0.59 土 
0.11 lamol/g 24 hr after administration of APAP. Co-administration of PSP (300 
mg/kg, i.p.) depleted hepatic GSSG further (by 65 % of controls) but the decrease 
was not statistically significant (P = 0.32). The GSSG/GSH ratio is an index of 
oxidative stress in liver or, more specifically, the hepatocytes (Jaeschke, 
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figure 2.08. Effects of PSP on hepatic total glutathione ( GSH + GSSG) levels in rats 24 
^ after APAP-treatment. Rats were pretreated with APAP ( 1.5 g/kg, p.o. ) or 20 % • 
Tween 80 in saline, followed by PSP ( 300 mg/kg, i.p.) 6 hr later. Values represent mean 






Control APAP APAP + PSP 
Figure 2.09. Effects of PSP on hepatic reduced glutathione ( GSH ) levels in rats 24 hr 
after APAP-treatment. Rats were pretreated with APAP ( 1.5 g/kg, p.o.) or 20 % Tween 
in saline, followed by PSP ( 300 mg/kg, i.p.) 6 hr later. Values represent mean 士 S.E. 
of five rats. ** Indicates significant difference from controls at P < 0.01. 
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Figure 2.10. Effects of PSP on hepatic oxidised glutathione ( GSSG ) levels in rats 24 hr 
after APAP-treatment. Rats were pretreated with APAP (1.5 g/kg, p.o.) or 20 % Tween 
80 in saline, followed by PSP ( 300 mg/kg, i.p.) 6 hr later. Values represent mean 士 S.E. 
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Figure 2.11. Effects of PSP on hepatic GSSG/GSH ratios in rats 24 hr after APAP-
treatment. Rats were pretreated with APAP ( 1.5 g/kg，p.o.) or 20 % Tween 80 in saline, 
followed by PSP ( 300 mg/kg, i.p.) 6 hr later. Values represent mean 土 S.E. of five rats. + 
Indicates significant difference from APAP group at P < 0.05. 
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1990). In the present study, co-administration of PSP (300 mg/kg, i.p.) with 
APAP (1.5 g/kg, P.O.) significantly reduced GSSG/GSH ratio from 0.25 士 0.04 in 
APAP-treated rats to 0.11 土 0.03 (by 56 %), as shown in Figure 2.11. 
Intraperitoneal administration of PSP (300 mg/kg) significantly reduced 
hepatic total glutathione by 18 %, from control level of 6.32 士 0.24 [xmol/g to 
5.16 土 0.28 |imol/g 6 hr after administration of PSP, as shown in Figure 2.12. 
However, the total glutathione (GSH + GSSG) level returned to an elevated level 
above the control level (by 2 %) 12 hr after administration of PSP. The increase 
in total glutathione (GSH + GSSG) continued to rise to 6.93 土 0.35 ^mol/g 18 hr 
after PSP administration, which represented an increase of 10 % above controls. 
The same phenomenon was observed in hepatic GSH level. As shown in Figure 
2.13，hepatic GSH content was significantly reduced by 15 % from 6.06 土 0.18 
^mol/g in control group to 5.12 士 0.24 |imol/g 6 hr after administration of PSP. 
Like the total glutathione (GSH + GSSG) level, the reduced glutathione (GSH) 
level subsequently returned and even overshot the control level. At 12 hr after the 
administration of the PSP, the hepatic GSH content was only 4 % lower than the 
control level. At 18 hr after administration of PSP, the hepatic content of GSH 
was 6.49 士 0.29 |imol/g, which was 7 % above the control level, but this increase 
was not statistically significant. The liver content of oxidized glutathione (GSSG) 
in the control group was 0.13 士 0.04 |imol/g. Six hours after the administration of 
PSP, the GSSG level in liver increased by 28 % to 0.16 土 0.03 |imol/g. The 
increase continued such that the hepatic GSSG level 12 hr after administration of 
PSP was significantly higher than the control level by 3 folds. However, there 
was a reduction of the elevated level of hepatic GSSG 18 hr after administration 
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Figure 2.12. Effects of PSP on hepatic total glutathione ( GSH + GSSG ) levels in rats 
during 18 hr after PSP-treatment. Rats were administered with PSP ( 300 mg/kg, i.p.) or 
saline. Values represent mean 土 S.E. of six to ten rats. ** Indicates significant difference 
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Figure 2.13. Effects of PSP on hepatic reduced glutathione ( GSH ) levels in rats during 
18 hr after PSP-treatment. Rats were administered with PSP ( 300 mg/kg, i.p.) or saline. 
Values represent mean 土 S.E. of six to ten rats. •* Indicates significant difference from 
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Figure 2.14. Effects of PSP on hepatic oxidised glutathione ( GSSG) levels in rats during 
18 hr after PSP-treatment. Rats were administered with PSP ( 300 mg/kg, i.p.) or saline. 
Values represent mean 土 S.E. of six to ten rats. *** Indicates significant difference from 
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Figure 2.15. Effects of PSP on hepatic GSSG/GSH ratios in rats during 18 hr after PSP-
treatment. Rats were administered with PSP ( 300 mg/kg, i.p.) or saline. Values represent 




higher than the control level, as shown in Figure 2.14. The GSSG/GSH ratio in 
control group was 0.021 土 0.006, and increased by 59 % to 0.033 士 0.006 six 
hours after PSP administration. The increase of GSSG/GSH ratio continued and 
become statistically significant, reaching 0 . 0 8 9 土 0 . 0 1 3 which was 3-fold the 
control value 12 hr after PSP administration. At 18 hr after PSP administration, 
the GSSG/GSH ratio was 85 % above the control level, however, this elevated 
ratio was not statistically significant (Figure 2.15). As shown in Figure 2.16, 
intraperitoneal administration of PSP (300 mg/kg) increased total glutathione 
(GSH + GSSG) level in blood but did not attain statistically significant level. The 
total glutathione (GSH + GSSG) level increased progressively, and reached the 
highest level (0.312 土 0.034 mM^at 12 hr after administration of PSP which was 
about 24 % above controls (0.252 土 0.022 mM). The same phenomena were 
observed in GSH level in blood (Figure 2.17); the GSH level increased 
progressively after PSP was administered (300 mg/kg, i.p.) and the highest level 
of GSH (0.266 士 0.026 mM) was found at 12 hr after administration of PSP 
(increased by 16 % of controls, 0.228 士 0.020 mM). However, the PSP-induced 
increase in blood GSH level was not statistically significant. Intraperitoneal 
administration of PSP (300 mg/kg) also resulted in a progressive increase of 
GSSG level in blood (Figure 2.18)，such that the GSSG level increased by 70 % 
from control level (0.012 士 0.005 mM) to 0.020 土 0.002 mM at 6 hr and 
increased by 94 % to 0.023 士 0.005 mM at 12 hr after PSP was administered. 
However, at 18 hr after administration of PSP, the elevated level of GSSG in 
blood was decreased (0.016 士 0.006 mM), but was still 36 % above controls. PSP 
(300 mg/kg, i.p.) induced the greatest increase in GSSG/GSH ratio in blood from 
0.056 士 0.024 in control rats to 0.091 土 0.011 at 6 hr after PSP was administered 
(by 62 %). The elevated GSSG/GSH ratio in blood was decreased 
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Figure 2.16. Effects of PSP on blood total glutathione ( GSH + GSSG ) levels in rats 
during 18 hr after PSP-treatment. Rats were administered with PSP ( 300 mg/kg, i.p.) or 
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figure 2.17. Effects of PSP on blood reduced glutathione ( GSH) levels in rats during 18 
f after PSP-treatment. Rats were administered with PSP ( 300 mg/kg, i.p. ) or saline. 
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？S^re 2-18. Effects of PSP on blood oxidised glutathione ( GSSG ) levels in rats during 
« hr after PSP-treatment. Rats were administered with PSP ( 300 mg/kg, i.p.) or saline 
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Figure 2.19. Effects of PSP on blood GSSG/GSH ratios in rats during 18 hr after PSP-
treatment. Rats were administered with PSP ( 300 mg/kg, i.p.) or saline. Values represent 
mean 土 S.E. of six to ten rats. 
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progressively thereafter, and the GSSG/GSH ratio was 51 % above controls at 12 
hr and fiirther decreased to control level at 18 hr after administration of PSP, as 
shown in Figure 2.19. 
2.3.2.2 Sub-chronic effects of polysaccharide-peptide (PSP) on hepatic 
glutathione 
To study the sub-chronic effects of PSP on hepatic glutathione, PSP was 》 
administered intraperitoneally at various doses (100, 200，300 and 400 
mg/kg/day) for 7 days. No significant change of hepatic total glutathione (GSH + 
GSSG) content were observed- at doses of PSP 100 and 200 mg/kg/day, 
respectively. However, total glutathione (GSH + GSSG) was reduced ’ 
！ 
significantly from 6.98 士 0.26 iimol/g in the controls to 4.89 土 0.22 |imol/g in 
rats treated with 300 mg/kg/day of PSP and to 4.84 土 0.28 |imol/g in rats with 
400 mg/kg/day of PSP, as shown in Figure 2.20. The extents of reductions were 
about 30 % and 31 % at doses of 300 and 400 mg/kg/day, respectively. Hepatic 
reduced glutathione (GSH) of the controls was 6.19 土 0.18 ^imol/g. 
Intraperitoneal administrations of various doses of PSP (100, 200, 300 and 400 
mg/kg/day) reduced the GSH level from the control level to 5.62 士 0.31, 5.55 土 
0.31, 3.74 土 0.10 and 3.74 士 0.17 ！imol/g, respectively, as shown in Figure 2.21. 
The extents of reductions of GSH level were about 9 %, 10 %，40 % and 40 % at 
increasing doses of PSP. Dose-dependent reductions of hepatic GSH content with 
increasing doses of PSP were thus observed. PSP (100 mg/kg/day, i.p.) increased 
the hepatic oxidized glutathione (GSSG) level from 0.39 士 0.08 |imol/g in 
controls to 0.52 土 0.08 jimol/g, the extent of increase was about 32 % of the 
control level. Doses of PSP (200 and 300 mg/kg/day) increased significantly 
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Figure 2.20. Dose-response of PSP on hepatic total glutathione ( GSH + GSSG) levels in 
rats after sub-chronic PSP administrations. Rats were administered with PSP ( 100-400 
mg/kg/day, i.p.) or saline for 7 days. Values represent mean 土 S.E. of ten to eighteen rats. 
*** Indicates significant difference from controls atP < 0.001. 
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Figure 2.21. Dose-response of PSP on hepatic reduced glutathione ( GSH ) levels in rats 
after sub-chronic PSP administrations. Rats were administered with PSP ( 100-400 
mg/kg/day, i.p.) or saline for 7 days. Values represent mean 士 S.E. of ten to eighteen rats. 
* Indicates significant difference from controls at P < 0.05; *** indicates significant 
difference from controls at P < 0.001. 
« 
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shown in Figure 2.22. These respective increases were 83 % and 50 % higher 
than the control level. However, the dose of PSP (400 mg/kg/day, i.p.) could only 
increase hepatic GSSG level by 23 % to 0.48 土 0.05 |xmol/g. As shown in Figure 
2.23, the dose of PSP (100 mg/kg/day, i.p.) increased the GSSG/GSH ratio by 54 
% from the control level (0.063 士 0.012) to 0.097 土 0.018. However, PSP at 
doses of 200, 300 and 400 mg/kg/day increased significantly the GSSG/GSH 
ratio by 123 %, 146 % and 102 %, respectively. The ratio increased from the 
control level to 0.141 土 0.018，0.156 土 0.015 and 0.128 土 0.010 at increasing 
t 
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Figure 2.22. Dose-response of PSP on hepatic oxidised glutathione ( GSSG ) levels in rats 
after sub-chronic PSP administrations. Rats were administered with PSP ( 100-400 
mg/kg/day, i.p.) or saline for 7 days. Values represent mean 土 S.E. of ten to eighteen rats. 
Indicates significant difference from controls at P < 0.05. 
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Figure 2.23. Dose-response of PSP on hepatic GSSG/GSH ratios in rats after sub-chronic 
PSP administrations. Rats were administered with PSP ( 100-400 mg/kg/day, i.p. ) or 
saline for 7 days. Values represent mean 士 S.E. of ten to eighteen rats. * Indicates 
significant difference from controls at P < 0.05; •** indicates significant difference from 
controls at P< 0.001. 
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2.4 Discussions 
Various methods have been used to monitor the degree of liver damage 
caused by the APAP toxicity, including measurements of alkaline phosphatase 
activities (Muriel et al., 1992), bromosulphthalein clearance (Khedun et al., 
1992), glucose concentration or rate of glucose formation (Khedun et al., 1992), 
y-glutamyl transpeptidase activities (Muriel et aL, 1992), glutamate-pyruvate 
transaminase activities (Hazelton et aL, 1986; Martinelli et aL, 1989; Siegers and 
Moller-Hartmann, 1989; Gilani and Janbaz, 1993; Harvey et al., 1993; L'm et al., 
1993; Yamada et al., 1993)，glutamate-oxaloacetate transaminase activities 
(Hazelton et al., 1986; Martinelli aL, 1989; Harvey et al., 1993; Yamada et al, 
1993), lactate dehydrogenase activities (Nasseri-Sina et al., 1992; Miller et al, 
1993)，sorbitol dehydrogenase activities (Siegers and Moller-Hartmann, 1989; 
Harvey et aL, 1993; Liu et aL, 1993) and lactate levels or lactate : pyruvate ratio 
(Khedun et aL, 1992) in plasma or perfusate (in isolated perfusion experiment), 
or liver hemoglobin concentration (Walker et aL, 1981) and histological 
observations (Mitchell et al., 1973; Khedun et al.’ 1992; Liu et al., 1993; Miller 
et al., 1993). Among these methods, plasma levels of glutamate-oxaloacetate 
transaminase (GOT; EC 2.6.1.1) and glutamate-pyruvate transaminase (GPT; 
2.6.1.2) have been used most frequently. GOT is an ectoenzyme of the cell 
plasma membrane; an increase in plasma GOT activity has been related to 
damage to the liver cell membrane. On the other hand, GPT is a cytosolic enzyme 
of the liver cells and an increase in the plasma level of this enzyme reflects an 
increase in plasma membrane permeability, which in turn, is associated with cell 
death (Muriel et aL, 1992). Large overdoses of APAP can produce dose-
dependent centrilobular hepatic necrosis and elevation of plasma transaminases 
activities (Mitchell et al., 1973; Hazelton et al., 1986; Welty et aL, 1992). 
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Hepatotoxicity data in the Sprague-Dawley rat show that APAP is minimally 
hepatotoxic at dose levels up to 1.5 g/kg where significant mortality begins to 
occur (Miller et al.�1993), accompanied by marked elevations of serum GOT and 
GPT 24 hr after administration of APAP (Gilani and Janbaz, 1993). APAP at 
doses of 300-750 mg/kg is hepatotoxic to mice which wil l cause centrilobular 
necrosis in liver and marked elevations in serum transaminases activities (Jollow 
et al, 1973; Mitchell et al� 1973; Walker et al, 1981; Jaeschke, 1990). 
In the present study, plasma GOT and GPT activities were used to monitor 
the integrities of rat and mouse livers, and damage caused by the hepatotoxicity 
of APAP resulted in elevations of plasma levels of these transaminases activities 
(Hazelton et aL, 1986; Siegers and Moller-Hartmann, 1989; Jaeschke, 1990; 
James et aL, 1992; Muriel et aL, 1992; Liu et aL, 1993). One Sigma-Frankel unit 
(SF unit) refers to the activities of transaminases that wil l form 4.82 x lO""^  ^imol 
glutamate per min (Lindamood, 1991). Oral administration of APAP (1.5 g/kg) 
into rats resulted in an 8-fold increase in plasma level of GOT and a 4-fold 
increase in plasma GPT activities 24 hr after the administration of APAP. Both 
these transaminases activities were significantly higher than controls. On the 
other hand, intraperitoneal administration of APAP (300 mg/kg) into mice 
induced a 535-fold elevation of plasma GPT activities 24 hr after APAP was 
administered. Therefore, the doses of APAP had caused significant damage to 
liver, and resulted in maximum releases of GOT and GPT into plasma 24 hr after 
APAP administration (Hazelton et aL, 1986; Siegers and Moller-Hartmann, 1989; 
Jaeschke, 1990; James et al., 1992; Welty et al., 1992; Gilani and Janbaz, 1993; 
Harvey et al., 1993; Liu et al., 1993; Yamada et al., 1993). Intraperitoneal 
administration of PSP (300 mg/kg) into rats 6 hr after the p.o. administration of 
« 
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APAP significantly reduced the elevations of plasma transaminases activities 
induced by APAP-hepatotoxicity. After the treatment of PSP, plasma GOT level 
was about 300 SF units/ml lower than those with APAP treatment alone, and was 
only slightly higher than controls. GPT level in rats treated with PSP was 320 SF 
units/ml lower than those with APAP treatment alone and was only slightly 
higher than the control level. As indicated by the significant reductions of GOT 
and GPT activities, PSP protected rat liver against the toxicity of APAP and 
maintained the integrity of the organ. To further confirm that PSP was protective 
against APAP-hepatotoxicity, PSP (200 mg/kg, i.p.) was given to C57 mice 6 hr 
after i.p. administration of APAP (300 mg/kg). This dose of PSP reduced APAP-
induced elevation of plasma GPT activities by 29 %，showing that PSP protected 
mouse liver against APAP-toxicity and maintained the organ integrity. Therefore, 
PSP was protective against the hepatotoxicity induced by overdosage of APAP 
both in Sprague-Dawley rats and C57 mice. The next logical step is to investigate 
the mechanism of PSP in protecting against APAP-induced hepatotoxicity. 
As discussed in section 1.2.3, the APAP-induced toxicity depends on 
factors which influence the balance between the rate of formation of A^-acetyl-p-
benzoquinoneimine (NAPQI) and the maximum rate of glutathione synthesis. 
Since the prevention of APAP-induced depletion of glutathione may belong to 
one of the most efficient methods of direct protection against APAP-
hepatotoxicity (Vermeulen et aL, 1992)，the effects of PSP on hepatic glutathione 
was studied. Glutathione (L-y-glutamyl-L-cysteinylglycine) is a cysteine-
containing tripeptide and is the most abundant non-protein thiol in mammalian 
cells. Glutathione plays a number of important physiological roles, including 
storage of cysteine, regulation of cellular redox balance, leukotriene and 
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prostaglandin metabolism, deoxyribonucleotide synthesis, immune function and 
cell proliferation (Bray and Taylor, 1993). Glutathione is also important in the 
detoxification of xenobiotic compounds and for the antioxidation of reactive 
oxygen species and free radicals. Glutathione-5'-transferase (EC 2.5.1.18), 
glutathione peroxidase (EC 1.11.1.9) and glutathione reductase (EC 1.6.4.2) play 
important roles in catalyzing the above reactions (Reicks and Cranshaw, 1993). 
The intrahepatic concentration of glutathione in Sprague-Dawley rats has been 
estimated to be about 5 to 8 ^imol/g (Tateishi and Higashi, 1978; Lauterburg et 
al, 1984). In the present study, the intrahepatic concentration of glutathione was 
estimated to be 6.32 土 0.24 to 7.27 土 0.50 [imol/g which was consistent with the 
previously determined hepatic glutathione concentration under normal 
physiological conditions. PSP (300 mg/kg) was administered intraperitoneally 
into rats 6 hr after oral administration of APAP (1.5 g/kg) and hepatic glutathione 
levels were determined 24 hr after APAP was administered. The dose of APAP 
significantly depleted total glutathione (GSH + GSSG), reduced glutathione 
(GSH) and oxidized glutathione (GSSG) in liver, but accompanied by a small 
increase in oxidative stress (GSSG/GSH ratio). The present observations were 
consistent with previous reports that excess amount of APAP was activated to 
NAPQI and conjugated with GSH in liver. The glutathione conjugate (APAP-
GSH) was then excreted out of liver and resulted in an overall loss of hepatic 
glutathione (Mitchell et al., 1973; Fischer et al., 1981; Fischer et aL, 1984; 
Miners et aL, 1984; Madhu et al., 1988; James et al., 1992; Dalhoff and Poulsen, 
1993; Miller et aL, 1993). In the present study, the dose of APAP only induced a 
slight increase in oxidative stress in liver (by 19 % of controls) but did not attain 
statistically significant level. GSSG/GSH ratio was unaffected by APAP-induced 
depletion of hepatic glutathione, and the ratio would increase only during 
recovery phase of depleted hepatic glutathione level (Jaeschke, 1990). Co-
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administration of PSP with APAP slightly increased the APAP-depleted hepatic 
total glutathione (GSH + GSSG) and GSH levels, but the increases did not reach 
statistically significant levels. However, when PSP was co-administered with 
APAP there was a further depletion of hepatic GSSG level and a significant 
decrease of GSSG/GSH ratio (by 56 % of APAP-treated rats). The results 
indicated that the interactions of APAP with PSP decreased oxidative stress in 
liver, and might be one of the possible means to protect liver against APAP-
toxicity (section 1.2.2.2). Allopurinol (Jaeschke, 1990), gomisin A (Yamada et 
al, 1993) and silymarin (Muriel et al., 1992) can protect against APAP 
intoxication through their antioxidant properties, possibly acting as free-radical 
scavengers. PSP may act like the other antioxidants which reduce the oxidative 
stress in liver and protect it against APAP-toxicity. 
In this study, the hepatoprotective actions of PSP were generated within 
the 18 hr after administration of PSP (section 2.2.3). Therefore, the effects of PSP 
on glutathione in liver and blood during the 18 hr after its administration were 
studied. Intraperitoneal administration of PSP (300 mg/kg) into rats decreased 
hepatic total glutathione (GSH + GSSG) and reduced glutathione (GSH) levels 
by 18 % and 15 %, respectively, 6 hr after its administration. However, 12 hr 
after administration of PSP, both hepatic total glutathione (GSH + GSSG) and 
GSH levels replenished and were only 2 % and 4 %, respectively, below the 
control levels. At 18 hr after administration of PSP, both the total glutathione 
(GSH + GSSG) and GSH levels were higher than the control levels. Although the 
increases were not statistically significant, the respective increases of total 
glutathione (GSH + GSSG) and GSH were 10 % (P = 0.15) and 7 % (P = 0.07) 
higher than the controls. Therefore, PSP was unlikely to exert its protective 
7 0 
actions against APAP-toxicity by increasing glutathione for conjugation to the 
chemically-reactive metabolite of APAP, since it did not increase the hepatic 
glutathione concentrations significantly within the 18 hr after its administration. 
Contrary to the expectation, PSP even depleted hepatic glutathione level 6 hr 
after it was administered in this study. Hepatocytes can maintain adequate 
intracellular concentrations of glutathione by rapidly increasing the rate of 
synthesis in order to compensate for losses of glutathione from the cell via efflux, 
catabolism, or conjugate formation (Lauterberg et al., 1984). Depletion of hepatic 
glutathione wil l be followed by a rapid increase in its rate of synthesis which 
leads to a concentration higher than normally found at the peak concentration of 
the diurnal rhythm of rats (Tateishi and Higashi, 1978). This was also confirmed 
indirectly by studies where hepatic glutathione was increased only in animals in 
which glutathione has been previously depleted (Hazelton et al., 1986). The 
reduction of hepatic glutathione may be due to several possible mechanisms. 
Firstly, the depletions may be due to the increased hepatic export of either/both 
GSH or/and oxidized glutathione (GSSG). The liver is the major organ for 
synthesis and export of glutathione to the plasma (Lauterberg et al., 1984). The 
capacity of the sinusoidal GSH transporter is markedly influenced by thiol-
disulphide status (Lu et al., 1993). Critical thiol(s) of the transporter protein 
and/or an adjacent regulatory protein exposed to the external environment may 
undergo mixed disulphide formation with protein disulphide formation leading to 
inhibition of GSH efflux. Liver has two GSSG transport systems. One of them 
involves excretion into bile through canalicular membranes, which is ATP-driven 
and carrier-mediated. The other is sinusoidal GSSG efflux under oxidative stress 
and is driven by the K+ concentration gradient across plasma membrane 
accompanying the efflux of K+ (Masuda et al., 1993). About 20 equivalents of K+ 
may be transported per mole of GSSG, and the efflux of GSSG from the 
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hepatocytes utilized the energy of the K+ efflux down the concentration gradient. 
Increased GSSG/GSH ratio could modify plasma membrane proteins by 
disulphide or mixed sulphide formation and caused changes in membrane 
permeability. The above mechanisms are important factors in interorgan 
homeostasis of glutathione because changes in the availability of thiol 
constituents in serum (because of changes in dietary intake or extrahepatic 
breakdown of glutathione to thiol-containing amino acids e.g. cysteine and its 
auto-oxidation to cystine) can signal the liver to alter its release of glutathione. 
The oxidative stress induced by the metabolism of PSP may increase the hepatic 
discharge of glutathione in the systemic circulation. To test the postulation that 
PSP affected hepatic release of glutathione into systemic circulation, glutathione 
levels and its status in blood were measured during the 18 hr after PSP was 
administered into rats. When PSP (300 mg/kg, i.p.) was administered, blood total 
glutathione (GSH + GSSG) levels increased progressively and reached the 
highest level (24 % above controls) 12 hr after PSP administration. Thereafter, 
the total glutathione (GSH + GSSG) level decreased and was only 17 % above 
controls 18 hr after PSP was administered. Similar patterns of changes of blood 
GSH and GSSG were observed, and the highest levels of GSH (16 % above 
controls) and GSSG (94 % above controls) were observed at 12 hr after PSP 
administration. Beside increasing glutathione levels in blood PSP also increased 
the GSSG/GSH ratio, and the highest value (62 % above controls) was observed 
at 6 hr after PSP was administered. The elevated GSSG/GSH ratio in blood then 
decreased and was similar to the control level 18 hr after PSP administration. The 
increases in blood glutathione levels, possibly, were due to increased hepatic 
release of glutathione into systemic circulation, mainly in form of GSSG, and led 
to elevated GSSG/GSH ratio. PSP is a protein-bound polysaccharide, and the 
、 peptide portion comprises considerable amount of sulphur-containing amino 
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acids, cystine and methionine (section 1.1). PSP or its metabolite(s) may affect 
glutathione status in liver and blood as other sulphydryl xenobiotics do, such as 
bucillamine, captopril and D-penicillamine (Yeung, 1992). Besides the PSP-
induced discharge of hepatic glutathione into blood, PSP or/and its metabolite(s) 
may also conjugate directly with glutathione, and the conjugates were then 
released into blood and/or bile. This conjugation wil l deplete hepatic glutathione 
level. This possibility cannot be excluded since the metabolic pathway of PSP 
has yet to be established, and further investigation is needed. Thirdly, PSP or/and 
its metabolite(s) may affect the synthesis of glutathione. Glutathione, synthesis 
takes place in 2 steps, and are tightly regulated. The initial rate-limiting step is 
catalyzed by y-glutamylcysteine synthetase (GCS) to y-glutamylcysteine. In the 
second step, glutathione synthetase catalyses the reaction between glycine and y-
glutamylcysteine to form glutathione (Bray and Taylor, 1993). Glutathione 
regulates its own synthesis by feedback inhibition of the rate-limiting step, the 
formation of y-glutamylcysteine by GCS (Lauterberg et al., 1984). This wi l l 
appear to be an important regulatory mechanism, which limits the maximum 
tissue concentration of glutathione in vivo (Bray and Taylor, 1993). Buthionine 
sulphoximine, a specific inhibitor of GCS can deplete hepatic glutathione by 38 
o/o (Miners et aL, 1984; Dalhoff and Poulsen，1993). Since the synthesis of 
glutathione is rate-limited by the formation of y-glutamylcysteine, the supply of 
cysteine is determining. Plasma cysteine concentrations are relatively low, and its 
intrahepatic concentration is just about equal to the K^ of cysteine for GCS, the 
supply of cysteine for glutathione synthesis has to depend on other sources. Both 
in vivo and in vitro, methionine can be utilized for glutathione synthesis via its 
conversion to cysteine through the cystathionine pathway (Reed and Beatty, 
1978). Methionine furnishes the sulphur atom and serine furnishes the carbon 
skeleton in the synthesis of cysteine. Beside cystathione pathway, a further 
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source of cysteine is the catabolism of proteins. Protein catabolism can probably 
not satisfy an acutely increased demand of cysteine, but under basal physiologic 
conditions, protein turnover provides as much as 50 % of the cysteine used for 
glutathione synthesis (Lauterberg et aL, 1984). Furthermore, cysteine can be 
originated from the catabolism of glutathione itself. Most of the glutathione 
turnover in liver in vivo under basal conditions is accounted for by efflux on the 
sinusoidal side of the hepatocyte into plasma and to a lesser extent by biliary 
excretion. Glutathione in plasma is rapidly catabolized, mainly in kidney and to a 
lesser extent in the lung, as evident by the high activity of y-glutamyltransferase 
activity in these tissues. Gamma-glutamytransferase is responsible for 
extracellular degradation of glutathione to cysteinylglycine，and y-glutamyl 
amino acids. After uptake into the cell, these dipeptides are further metabolized 
to the amino acid constituents of glutathione by dipeptidases, and y-glutamyl 
cyclotransferase and oxoprolinase, and are available for intracellular glutathione 
or protein synthesis (Jones et aL, 1978). On the other hand, biliary glutathione is 
rapidly metabolized to its constituent amino acids by the intestinal transferase 
and peptidases. The cysteine originating from glutathione catabolism is recovered 
by kidneys and also by intestinal absorption and re-enter the precursor pool for 
glutathione synthesis (Bray and Taylor, 1993). The direct inhibitory effects of 
PSP on glutathione synthesis or indirect effects through reduced supply of 
cysteine cannot be ruled out. After the administration of PSP oxidized glutathione 
(GSSG) increased to 1.3 folds of control level at 6 hr, and further increased to a 
significantly higher level (3.2 folds of controls) at 12 hr after PSP was 
administered. However, at 18 hr after PSP administration, GSSG level was only 
80 % higher than controls. GSSG/GSH ratio has been used as an index of 
oxidative stress in liver (Jaesehke，1990). Accompanying the changes of hepatic 
GSSG level throughout the 18 hr after administration of PSP, a similar pattern of 
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changes of GSSG/GSH was observed. The ratio increased to 1.6 folds of controls 
at 6 hr, and increased to a significantly higher level which was about 3.3 folds of 
controls at 12 hr after PSP was administered. However, at 18 hr after 
administration of PSP, the GSSG/GSH ratio was only 86 % higher than controls. 
The results indicated that the metabolism of PSP generated an oxidative stress in 
liver. Both the increased hepatic GSSG level and GSSG/GSH ratio may be due to 
the replenishments of depleted glutathione levels, since during the recovery phase 
the GSSG content would increase faster than GSH resulting in an increased 
GSSG/GSH ratio (Jaesehke, 1990). During the recovery phase of hepatic 
glutathione from 6 to 12 hr after administration of PSP, GSH increased only by 
14 %, while GSSG increased by 168 % which was 12 folds greater than that of 
GSH. Both the high hepatic levels of GSSG and GSSG/GSH become lower at 18 
hr after PSP was administered. The reductions were probably due to positive 
feedback effects on glutathione reductase which reduced GSSG back to GSH; or 
alternatively, the reductions may be due to the increased hepatic release of GSSG 
into the systemic circulation. Both these processes can release the oxidative stress 
in the hepatocytes induced by PSP. 
To study the sub-chronic effects of PSP on hepatic glutathione, various 
doses of PSP were administered intraperitoneally into rats for 7 days. Little 
changes in hepatic total glutathione (GSH + GSSG) were observed at either 100 
or 200 mg/kg/day of PSP. However, at doses of 300 and 400 mg/kg/day of PSP, 
hepatic total glutathione (GSH + GSSG) were reduced by 30 % and 31 %, 
respectively. In comparison with single dose effect of PSP (300 mg/kg) on 
hepatic total glutathione (GSH + GSSG) (depleted by 18 %), sub-chronic 
administrations of PSP (300 mg/kg/day) induced a greater extent of reduction (by 
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30 %). Furthermore, 300 mg/kg/day of PSP was the threshold dose for hepatic 
total glutathione (GSH + GSSG) reduction, since further increased the dose of 
PSP (to 400 mg/kg/day) did not reduce total glutathione (GSH + GSSG) further. 
On the other hand, increasing doses of PSP from 100 to 400 mg/kg/day caused 
dose-dependent reductions of hepatic GSH from 9 % to 40 %. In comparison 
with acute effects of PSP (300 mg/kg) on hepatic GSH (reduced by 15 %), PSP 
(300 mg/kg/day) when administered sub-chronically reduced hepatic GSH by a 
greater extent (40 %). Same as hepatic total glutathione (GSH + GSSG), the 
threshold dose for hepatic GSH reduction was observed at 300 mg/kg/day since 
increasing the dose did not reduce the GSH level further. Increased extents of 
reductions of both total glutathione (GSH + GSSG) and GSH under sub-chronic 
administrations of PSP may account for the higher level(s) of PSP or/and its 
metabolite(s) present in the animal body under the prolonged treatment. The sub-
chronic administrations of PSP (100 mg/kg/day) increased the oxidized 
glutathione (GSSG) by about 32 %. Further increasing the dose of PSP to 200 
mg/kg/day caused a significant increment of GSSG by 83 %; however, when the 
doses were increased to 300 and 400 mg/kg/day, the increases of GSSG levels 
were lower and just by 50 % and 23 %, respectively. Since the GSSG/GSH ratio 
was used as an index of oxidative stress, and greater extents of hepatic GSH 
reductions were observed only at higher doses of PSP, a slightly different pattern 
of changes of GSSG/GSH ratio compared to GSSG level was observed. 
Increasing the doses of PSP from 100 to 300 mg/kg/day caused dose-dependent 
increases of GSSG/GSH ratio by 54 % to 146 %. However, at an even higher 
dose of PSP (400 mg/kg/day), significant increase of the ratio was still observed 
but the extent of increase was lower and just by 102 %. Therefore, the highest 
hepatic level of GSSG was observed at 200 mg/kg/day of PSP, while the highest 
ratio of GSSG/GSH was observed at 300 mg/kg/day of PSP. The difference was 
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due to a greater extent of depletion of hepatic GSH at 300 mg/kg/day, and 
resulted in higher ratio and oxidative stress. The reduced extents of increases of 
both the hepatic GSSG level and GSSG/GSH ratio at higher doses of PSP (300 
and 400 mg/kg/day) were unlikely due to the positive feedback effects of 
oxidative stress on glutathione reductase activities, since both the total 
glutathione (GSH + GSSG) and GSH were greatly reduced in the liver indicating 
a loss of hepatic glutathione. As discussed before, hepatic glutathione may be lost 
through hepatic discharge, conjugation or inhibition of hepatic glutathione 
synthesis. Jaeschke (1990) proposed that the depletion of hepatic glutathione 
would be accompanied by increased GSSG/GSH ratio, and the extremely 
elevated hepatic GSSG would induce folds of increase of plasma GSSG 
concentrations. This postulation was further supported by Yeung (1991) who 
found that administrations of increasing doses of bucillamine (a sulphydryl drug) 
produced a dose-dependent depletion (20-40 %) of hepatic GSH, while a 
significant dose-dependent increase in the plasma GSSG (by 2-7 folds) was 
observed. Since the present studies were focused on the effects of PSP on hepatic 
glutathione, the effects of various doses of PSP on blood glutathione need further 
studies. However, the administration of a single dose of PSP (300 mg/kg) 
induced elevations of blood glutathione levels may account for a similar hepatic 
loss of glutathione under sub-chronic administrations of PSP. On the other hand, 
at lower doses of PSP (100 and 200 mg/kg/day) only the hepatic GSH was 
significantly depleted but not total glutathione (GSH + GSSG), accompanied by 
significant increases of hepatic GSSG. These indicated that lower doses of PSP 
produced oxidative stress only but there is no overall loss of hepatic glutathione. 
In fact, highest GSSG/GSH ratio was observed after the administration of 300 
mg/kg/day of PSP, and was accompanied by losses of hepatic glutathione. 
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Therefore, PSP is protective against APAP-induced hepatotoxicity in rats 
and mice. One of the possible mechanisms of PSP protection is the reduction of 
oxidative stress in liver when PSP is co-administered with APAP. Less damage is 
thus caused to hepatocytes by APAP administration and the integrity of liver is 
maintained. However, unlike other common protective agents against APAP-
hepatotoxicity, the protective mechanism of PSP is unlikely to be due to direct 
conjugation of the chemically-reactive metabolite of APAP to glutathione, since 
PSP does not increase and may even deplete hepatic glutathione level after its 
administration. After the investigation of PSP effects on glutathione status, the 
next logical step is to study the effects of PSP on the covalent binding and 




Studies on the effects of polysaccharide-peptide (PSP) on the 
covalent binding and metabolism of paracetamol (APAP) 
3.1 Introduction 
Biotransformation plays a key role in toxicity and carcinogenicity; it 
sometimes can be a detoxification process but in general, it converts lipophilic 
xenobiotics to readily excretable water-soluble compounds. Many electrophilic, 
reactive species are generated during the biotransformation process. These 
electrophiles are chemically reactive with the basic cellular constituents: protein, 
RNA, and DNA. These chemical interactions can lead to disruption of normal 
cellular function and result in toxicity and carcinogenicity. The occurrence, 
degree, and extent of toxicity of a xenobiotic in a particular cell or organ depends 
primarily on whether the biotransformation process may produce a compound 
more or less toxic than the parent compound and the relative activities of 
enzymes generating and biotransforming the electrophiles to less reactive 
compounds. In general, biotransformation includes phase I and phase I I reactions. 
Phase I reactions convert the parent drug to a more polar metabolite by 
introducing or unmasking a functional group (-0H, -NH2, -SH). Quantitatively, 
90 0/0 of the phase I oxidation of xenobiotics is catalyzed by the cytochrome P450 
monooxygenase enzyme system (Lindamood, 1991). I f phase I metabolites are 
sufficiently polar, they may be readily excreted. However, many phase I products 
undergo a subsequent reaction in which an endogenous substrate such as 
glucuronic acid, sulphuric acid, acetic acid or an amino acid combines with the 
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newly established functional group to form a highly polar conjugate before they 
are excreted. 
For an ingested dose of APAP, about 80 % of the drug wil l be conjugated 
with glucuronic acid and sulphate before being excreted, and less than 5 % may 
be activated via a cytochrome P450 monooxygenase-catalyzed reaction to the 
highly reactive intermediate, A/'-acetyl-p-benzoquinoneimine (NAPQI). This 
electrophile may bind covalently to macromolecules, and/or may induce 
oxidative stress and changes in the calcium and/or thiol status (section 1.2.2). Al l 
these events contribute to APAP-induced necrosis of hepatocytes. Therefore, the 
bioactivation of APAP to NAPQI via cytochrome P450 monooxygenase-
catalyzed oxidation represents a crucial step in the hepatotoxicity of APAP. 
Basically, the cytochrome P450 system catalyses the insertion of an active 
oxygen species into a substrate molecule. As shown in Figure 3.01, the initial 
substrate binding event A is associated with a shift in the spin equilibrium of 
oxidized P450 from the low- to the high- spin component. The second step in the 
cycle, B, involves one electron reduction of high-spin ferric P450 supplied by 
NADPH via the flavoprotein NADPH cytochrome P450 reductase. Step C 
involves the binding of oxygen to form a ferrous P450 dioxygen intermediate, 
and D represents the transfer of a second electron to the intermediate from either 
NADH via cytochrome bs or NADPH via NADPH-cytochrome P450 reductase. 
Loss of water from the reduced dioxygen intermediate, E, and decomposition of 
the residual complex regenerates ferric P450 and oxidized substrate F (Murray, 
1987). Isoenzyme specificity exists in APAP oxidation. In rat liver microsomes, 
which resemble human liver microsomes with respect to the P450 expression 
80 
RH e" 
Fe+3 乂 * Fe+3.RH 乂 > Fe+2.RH 
(A) (B) 
A 〇2 
R O h f ^ (F) ( C ) 广 
Y 
(E) r (D) 
. 0 J / [0-2 丨〉1〇2 . 
H2O e" 
Figure 3.01. The cytochrome P450 reaction cycle. Refers to the text for 
the description of pathways A to F (adapted from Murray, 1987). 
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pattern, the IA2 form, in addition to the I IEl form, activated APAP with the 
affinity of the IA2 form for APAP lower than that of the I IEl form (Anundi et 
aL, 1992). The damage of hepatocytes in the centrilobular region of liver after 
high doses of APAP is mainly accounted by the zone-specific APAP activation, 
mediated by the regional expression of ethanol-inducible cytochrome P450 2E1 
(Anundi et al” 1992). 
As described in section 1.2.2, the chemically-reactive metabolite of APAP 
wi l l conjugate, normally, with reduced glutathione (GSH) and excreted as APAP-
mercapturate conjugate in urine. However, the hepatic pools of glutathione are 
limited (T1/2 = 1.7 hr and 28.5 hr, respectively) (Tateishi and Higashi，1978) and 
wi l l be readily depleted by a hepatotoxic dose of APAP. The unconjugated 
NAPQI wi l l then bind to vital cellular proteins and lead to cell death. After a 
hepatotoxic dose of APAP is administered to mice, nearly 85 % of the total 
detectable protein-bound APAP is covalently associated with proteins of 44 and 
58 kDa (Bartolone et al., 1988). Therefore, the specificity of APAP binding to 
proteins in vivo occurred in a very selective manner with most of the drug being 
covalently bound to proteins of 44 and 58 kDa, and very few of many other 
cytosolic proteins were arylated after APAP exposure. The 58 kDa APAP-
binding protein is a cytosolic monomer, while the 44-kDa protein is a subunit of 
a large protein complex which is a native to endoplasmic reticulum (Birge et al., 
1991). It is possible that APAP binding introduces a hydrophobic moiety that 
destabilizes ionic interactions between an intrinsic membrane protein and the 
peripheral 44 kDa containing protein complex. Alternatively, the oxidative 
properties of NAPQI may cause the endoplasmic reticulum membranes which 
stabilizes the 44 kDa APAP-bound protein complex to break up into small 
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vesicles. The cluster of 58 kDa proteins which binds APAP is among the highest 
thiol-containing cytosolic proteins; whereas, the major 44 kDa protein which 
avidly bound APAP contains only a bare amount of thiols, and the other proteins 
which exhibit a high thiol content do not apparently bind APAP. This argues that 
the protein susceptibility in APAP-toxicity is the result of both thiol reactivity 
and accessibility to the electrophile. The very high thiol content and apparent 
high reactivity of the 58 kDa proteins for NAPQI make it tempting to speculate 
on their possible role in protecting cells by sequestering reactive electrophilic 
species, such as NAPQI. On the other hand, since the major 44 kDa protein-
adduct appears to contain few free cysteine residues, it is possible that the cellular 
localization of proteins with respect to the site of cytochrome P450 activation is 
also a determinant of APAP binding (Bartolone et al., 1988). 
Apart from being oxidized by cytochrome P450 (phase I reaction), APAP 
wil l also be conjugated via sulphation or glucuronidation (phase I I reactions). 
Both sulphation and glucuronidation serve as first line defenses against APAP-
toxicity. Glucuronidation involves the translocation of glucuronic acid from 
UDP-glucuronic acid to the hydroxyl group of APAP to form the p-D-
glucuronide conjugate. This reaction is catalyzed by UDP-
glucuronosyltransferases (EC 2.8.2.1.). Several isoenzymes of UDP-
glucuronosyltransferases (UDPGTs) are believed to exist, and in rat liver, there 
are at least five isoenzymes; four are specific for endogenous bilirubin and 
steroids. Xenobiotic biotransformation appears to involve a fifth isoenzyme 
termed phenol-UDPGlMc (Lindamood, 1991). Sulphotransferases (EC 2.8.2.1.), 
on the other hand, are cytosolic enzymes present in liver, kidney, intestinal tract, 
and lungs. These enzymes play an important role in catalyzing the conjugation of 
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hydroxyl group of APAP with inorganic sulphate. The co-factor for these enzyme 
reactions is 3'-phosphoadenosine 5'-phosphosulphate (PAPS), the source of 
sulphate. In the cell, the major source of sulphate for PAPS synthesis is derived 
from cysteine oxidation. Since the free cysteine concentration in the cell is 
limited, PAPS concentration is rate-limiting for sulphate conjugation. Other than 
the regulatory effects of free cysteine concentration on PAPS availability, dietary 
sulphate or local concentration of sulphate are important determinants of 
sulphotransferase activities. 
In this study, the effect of PSP on the metabolism of APAP was 
investigated in vivo in the rat. The effect of PSP on the covalent binding of 
radiolabelled APAP in vitro was also studied to determine the underlying 
mechanism(s) of the protective effects of PSP on APAP-induced hepatotoxicity. 
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3.2 Materials and Methods 
3.2.1 Chemicals and reagents 
3 -Acetyl-/7-aminophenol, 4-acetyl~/>aminophenol (APAP), 4-acetyl-/7-
aminophenol-Ring-UL-^"^C (7.5 mCi/mmol), p-nicotinamide adenine dinucleotide 
phosphate (sodium salt，NADP)，bovine serum albumin, D-glucose-6-phosphate 
(monosodium salt), ethyl carbamate, glucose-6-phosphate dehydrogenase (Type 
V) and sodium potassium tartrate were purchased from Sigma Chemical Co. (St. 
Louis, Mo., U.S.A.). Di-sodium hydrogen phosphate dihydrate, potassium 
chloride, potassium dihydrogen phosphate, sodium hydrogen carbonate and 
sodium hydroxide were supplied by E. Merck (Darmstadt, Germany). Anhydrous 
copper sulphate, methanol (AR grade and HPLC grade) were obtained from 
Mallinckrodt Specialty Chemicals Co. (Paris, Kentucky, France). Ethyl acetate 
(HPLC grade) was purchased from Fluka (Buchs, Switzerland). Sodium acetate 
hydrated, sodium carbonate anhydrous and sodium chloride were supplied by 
BDH Limited (Poole, England). Magnesium chloride and trichloroacetic acid 
(TCA) were obtained from Ajax Chemicals (Auburn, Australia). 4-Acetyl-/7-
aminophenol-glucuronide (APAP-G) and 4-acetyl-/7-aminophenol-sulphate 
(APAP-S) conjugates were kindly donated by Sanofi Winthrop Production 
Division (England). Scintillation cocktail was purchased from LKB Scintillation 
Products (Leiss, England). Polysaccharide-peptide (PSP) was kindly supplied by 
Winsor Health Products Limited (Hong Kong). 
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3.2.2 Animals 
Male Sprague-Dawley rats (250-350 g)，obtained from Animal House 
(The Chinese University of Hong Kong, Hong Kong), were housed in groups of 5 
in stainless steel cages in a temperature- and humidity- controlled animal facility 
with a 12-hr light-dark cycle, and allowed rodent chow (PMI Feeds Inc., St. 
Louis, Mo., U.S.A.) and water ad libitum. Al l the rats were acclimated for at least 
1 week before use. 
3.2.3 Studies on the effects of polysaccharide-peptide (PSP) on 
the covalent binding of ["C]paracetamol ("C-APAP) to 
microsomal proteins in vitro 
3.2.3.1 Preparation of rat liver microsomes 
Male Sprague-Dawley rats (250-350 g) were sacrificed by cervical 
dislocation. Livers were removed and homogenized with a motor-driven glass-
Teflon homogenizer in five volumes of 0.01 M phosphate buffer, pH 7.4， 
containing 0.15 M KCl. The homogenate was centrifuged (10,000 x g) for 25 min 
at 4 °C (centrifuge J2-21, Beckman, U.S.A.). The supernatant was taken and 
centrifuged for 1 hr (105,000 x g) at 4。C (ultracentrifuge L7-65, Beckman, 
U.S.A.). The microsomal pellet was then washed 3 times each with 1 ml 
phosphate buffer (0.01 M, pH 7.4). The washed microsomal pellet was 
resuspensed in 0.01 M phosphate buffer (pH 7.4, containing 0.15 M KCl) and 
assayed for protein by the method of Lowry et al (1951), using bovine serum 
albumin as the protein standard. Microsomes from Sprague-Dawley rats pre-
treated with PSP (100 mg/kg/day; 10 mg/ml, given intraperitoneally for 7 days, 
參 
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and the last dose was given 6 hr before the rats were sacrificed) were prepared 
similarly. Control rats were injected i.p. with 0.15 M saline (10 m/kg) over the 
same period. 
3.2.3.2 Incubation of microsomal mixture 
The incubation was done by a modified method from Potter et al (1973). 
25-ml conical flasks each contained a final volume of 2.5 ml mixture: liver 
microsomal protein (5 mg; 300 |il of a 17 mg/ml microsomal protein 
preparation), 0.01 M phosphate buffer (pH 7.4, containing 0.15 M KCl), and a 
mixture (at least 4000 dpm/nmole) of 4-acetyl-j9-aminophenol (40 nmole/ml of 
incubation mixture; 10 mM, 10 jil) and 4-acetyl-p-aminophenol-Ring-lJL-^'^C 
(0.013 mCi/ml, 2 ^il). The flasks were equilibrated for 2 min in a waterbath with 
shaking (SWB 20, Haake, Germany) at 37 °C. The reaction was initiated by 
adding 0.5 ml of 0.01 M phosphate buffer (pH 7.4，containing 0.15 M KCl) with 
the following reduced nicotinamide adenine dinucleotide phosphate (NADPH)-
generating system: NADP (1.0 \xmo\\ MgCl〗(15 pmol), glucose-6-phosphate 
dehydrogenase (2 E.U.). Aliquots (each 200 ^il) were taken from each flask to 
determine the exact specific activity of radiolabelled paracetamol ("C-APAP) 
inside. 
The in vitro effect of PSP on covalent binding-time profile of "C-APAP 
was investigated by preparing microsomes from rats (n = 5)，with the addition of 
PSP (16.67 mg/ml of incubation mixture; 1 g/ml, 500 ^1) into the incubation. 
Controls (n = 5) were set up using only phosphate buffer (0.01 M, pH 7.4) in 
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place of PSP solution (500 |xl). Reactions were started by adding NADPH -
generating system (500 |il) and were carried out at 37 °C in a waterbath with 
shaking (SWB 20, Haake, Germany) for 2 hr, and were stopped at the appropriate 
times (every 15 min during first I1/2 hr and finally at 2 hr after incubation) by 
pouring the mixtures into test-tubes each containing 2 ml of 3 M trichloroacetic 
acid (TCA). The dose effect of PSP on the covalent binding of ''^C-APAP in vitro 
was studied by preparing microsomes from rats (n = 6)，and different doses of 
PSP (0.1667, 1.667 and 33.34 mg/ml; serial dilutions of 2 g/ml stock, 500 pi) 
were added into the incubation mixtures. Controls (n = 6) were set up using only 
phosphate buffer (0.01 M，pH 7.4) in place of PSP solution (500 ^il). Reactions 
were started by the addition of NADPH-generating system (500 |il), and were 
carried out at 37 °C in the waterbath with shaking for 30 min. After 30 min of 
incubation, the reactions were stopped by pouring the mixtures into test-tubes 
each containing 2 ml of 3 M TCA. On the other hand, the in vivo effect of PSP on 
in vitro covalent binding was studied by preparing microsomes from controls (n 
= 3 ) and PSP pre-treated rats (n = 5)，and incubated with '"^C-APAP. The 
reactions were started by adding NADPH-generating system (500 jil), and were 
carried out in the water bath at 37 °C with shaking for 30 min. After the 
incubation, the reactions were stopped by pouring the incubation mixtures into 
test-tubes each containing 2 ml of 3 M of TCA. Al l the TCA-precipitated proteins 
were then centrifuged at room temperature (1,000 x g) for 15 min. The 
supernatant was discarded, and the precipitated protein was washed twice in 3 ml 
of 0.6 M TCA and extracted with methanol (AR grade, each 3 ml) (Potter et al, 
1973) until no further radioactivity was detected in the supernatant (usually 7 
times). The extracted protein was dissolved in 1 ml of boiling 1 N NaOH and an 
aliquot (200 \i\) was added to a scintillation vial (Sarstedt, Germany) containing 4 
ml of scintillation cocktail (LKB Scintillation Products, Leiss, England) and 
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counted in a scintillation counter (LS 6000 SC, Beckman, U.S.A.). Radioactivity 
was corrected for background and for quench (external standardization). Protein 
concentration was determined according to Lowry et al (1951), using bovine 
serum albumin as the protein standard. The covalent binding was expressed as 
nmole of APAP/mg of microsomal proteins. 
3.2.4 Studies on the effects of polysaccharide-peptide (PSP) on the 
metabolism of paracetamol (APAP) 
Male Sprague-Dawley rats (250-350 g) were anaesthetized with ethyl 
carbamate (1.4 g/kg in 0.15 M NaCl; 0.14 g/ml, i.p.). Cannula (Portex Limited, 
England) were placed in the trachea, right jugular vein, left carotid artery, and 
common bile duct. In the pretreatment studies, PSP was administered at doses of 
100 or 200 mg/kg (40 mg/ml) in saline over 1 min via the jugular vein (n = 5). 
Controls (n = 8) received saline only. Thirty min after the administration of PSP, 
APAP (100 mg/kg in saline; 20 mg/ml) was administered over 1 min via the 
jugular vein. Blood samples (0.5 ml) were collected via carotid artery every 15 
min in heparinized microcentrifuge tube during the first hour after the 
administration of APAP. Subsequently, blood samples were collected at 30 min 
intervals. An equal volume of saline was administered via the jugular vein to 
replace the fluid volume of the blood collected. Bile samples were collected 
every 30 min throughout the 3-hr period of study. In the post-treatment study, the 
anaesthetized rats were treated identically as those of the pre-treatment studies, 
excepted that PSP (200 mg/kg; 40 mg/ml, i.v.) was administered 30 min after the 
intravenous administration of APAP (100 mg/kg; 20 mg/ml). At the end of 
studies, the anaesthetized rat was sacrificed by the administration of 2 ml of 1 M 
8 9 
potassium chloride solution. Plasma and bile were obtained and frozen (-20 °C) 
until analyzed. 
3.2.4.1 Measurements of APAP and its metabolites in plasma and 
bile by high performance liquid chromatography method 
APAP, APAP-S and APAP-G concentrations in plasma and bile were 
quantitated by high performance liquid chromatography. The mobile phase 
consisted of 8 % organic phase (2 ml of ethyl acetate for every 150 ml of 
methanol, HPLC grade) with 92 % acetate buffer (0.05 M, pH 3.6). The flow 
rate was 1 ml/min. In order to determine APAP, APAP-S and APAP-G levels in 
rat plasma, standard curves for metabolites were prepared, as shown in Figures 
3.02, 3.03 and 3.04, respectively. 500 \ig/m\ of APAP-S and 250 \ig/m\ of 
APAP-G standard solutions were prepared, respectively, in double distilled water 
with 5 % methanol (HPLC grade). 200 |Lig/ml of APAP and 100 |ag/ml of internal 
standard (3 -acetyl-/?-aminophenol) solutions were prepared, respectively, in 
warm double distilled water. APAP, APAP-S and APAP-G were added to each 
microcentrifuge tube as shown in Table 3.01. 25 [il of internal standard solution 
and 50 \i\ blank rat plasma were added. Then, 100 of saturated barium 
hydroxide and 100 |il of zinc sulphate solution (20 % zinc sulphate in double 
distilled water and methanol, HPLC grade, in 50:50 mixture) were added, 
respectively, to precipitate protein. After the addition of the solutions, the tubes 
were vortexed briefly, and were then centrifuged at 3,000 x g for 3 min (MSE 
microcentrifuge, England) .20 |il of supernatant was then injected with a 
microsyringe (Hamilton, England) into a Hewlett-Packard 1050 series HPLC 
system (Hewlett-Packard Co., Waldbronn, Germany) with a multiple wavelength 
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Millipore Corporation, Milford, U.S.A.). Peak height ratios of respective 
metabolites at different concentrations were measured. 
Another set of standard curves were prepared to measure APAP-S and 
APAP-G levels in rat bile, as shown in Figures 3.05 and 3.06, respectively. 1 
mg/ml of APAP-S and APAP-G standard solutions were prepared, respectively, 
in 5 o/o methanol (HPLC grade). 2 mg/ml of internal standard solution was 
prepared in double distilled water. APAP-S and APAP-G were added to each 
microcentrifuge tube as shown in Table 3.2. 50 blank bile together with 25 \i\ 
internal standard solution were added. 350 |il saturated barium hydroxide and 
350 \i\ zinc sulphate solution were added, respectively, to precipitate protein. The 
final mixtures were then vortexed and centrifuged at 3,000 x g for 30 min (MSE 
microcentrifuge, England) .20 of supernatant was injected into the HPLC 
system. Again, peak height ratios of respective metabolites at different 
concentrations were measured. Standard curves of APAP, APAP-S and APAP-G 
in plasma (10-160 jig/ml) and bile (200-2000 ^g/ml) were all linear (r > 0.99), 
and were prepared every time before an analysis was carried out. Under the 
above conditions, the retention times of APAP-G, APAP-S, APAP and the 
internal standard (3-acetyl-/>-aminophenol) were 3.0, 4.9, 7.3 and 10.8 min, 
respectively, as shown in Figures 3.07 and 3.08. 
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Figure 3.07. Chromatograph shows peaks of APAP-S, APAP-G, APAP and 3-
acetyl-p-aminophenol ( internal standard )，respectively, in rat plasma after the 
HPLC assay. Retention times for APAP-S, APAP-G, APAP and the internal 
standard are 3.0，4.9, 7.3 and 10.8 min, respectively. 
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Figure 3.08. Chromatograph shows peaks of APAP-S, APAP-G and 3-acetyl-p-
aminophenol ( internal standard )，respectively, in rat bile after the HPLC assay. 
Retention times for APAP-S, APAP-G and the internal standard are 3.0，4.9 and 
10.8 min, respectively. 
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3.2.4.2 Data analysis 
APAP plasma concentration-time data were analyzed according to a one-
compartment open model using the nonlinear least squares regression program 
TOPFIT (Version 1.0) in conjunction with a model-specific subroutine and a 
weighting function of l/(concentration). The area under curve (AUG) from zero 
to the last measured time point was calculated by the trapezoidal rule. 
Extrapolation of the AUG to infinity was made by adding the ratio between the 
last plasma concentration and the terminal elimination rate constant. The CLy-was 
estimated by the ratio of the APAP dose to the calculated AUG from zero to 
infinity. „ 
3.2.5 Statistic analysis 
An unpaired Student's t test was used for all comparisons between the 
treated and control groups. In all cases, the criterion for statistical significance 
was P < 0.05. Data are presented as the mean 土 S.E. 
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3.3 Results 
3.3.1 The effects of polysaccharide-peptide (PSP) on the covalent 
binding of radiolabeled paracetamol ("C-APAP) in vitro 
As shown in Figure 3.09, incubation of "^^ C-APAP with rat microsomes 
resulted in covalent binding of '^^ C-APAP to the microsomal proteins. The 
binding of "^^ C-APAP to the microsomal proteins was covalent in nature as 
repeated extractions (usually 7 times) with organic solvent (absolute methanol) 
did not alter the binding (Potter et al” 1973). The binding of '^^ C-APAP to 
microsomal proteins increased linearly with time during the first 30 min of 
incubation; 0.094 土 0.019 nmole of APAP was found to bind to each mg of 
microsomal proteins after 15 min of incubation, and the covalent binding 
increased to 0.212 士 0.030 nmole of APAP/mg of microsomal proteins after 30 
min of incubation. Thereafter, however, the increase of binding reached a 
maximum such that only 0.247 土 0.040 nmole of APAP was bound to each mg of 
microsomal proteins after further 120 min incubation. The results were consistent 
with those of Potter et al (1973) who found that the linearity of covalent binding 
of i 4 c - A P A P to rat microsomal proteins was a function of time, and at 10 mM of 
APAP the covalent binding would depart from linearity after 25 min of 
incubation. When PSP (16.67 mg/ml of incubation mixture) was incubated with 
"C-APAP and rat microsomes, covalent binding of "^^ C-APAP to the microsomal 
proteins in vitro was decreased by 56 % to 76 % throughout the 2 hr of 
incubation (Figure 3.09). The PSP-induced reduction of covalent binding was 
observed as early as after 15 min of incubation (0.042 土 0.004 nmole of 
APAP/mg of microsomal proteins, comparing to 0.094 士 0,019 nmole of 
APAP/mg of microsomal proteins in controls), the covalent binding had 
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Figure 3.09. Covalent binding-time profiles of ^^C-APAP to rat microsomal proteins in 
vitro. 14c-APAP alone ( • ) or together with 16.67 mg/ml of PSP ( • ) were incubated 
with the prepared microsomes for 2 hr. Values represent mean 土 S.E. of five rats. * 
Indicates significant difference from controls at P < 0.05; ** indicates significant 
difference from controls at P < 0.01. 
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binding by 66 % such that only 0.084 ±0.010 nmole of APAP was bound to each 
mg of microsomal proteins, comparing to 0.247 士 0.040 nmole of APAP/mg of 
microsomal proteins after the same time of incubation in controls. As observed in 
covalent binding-time profile of "C-APAP to microsomal proteins, the binding 
reached a maximum level after 30 min of incubation. Therefore, in investigating 
the dose effect of PSP on the covalent binding, various doses of PSP were 
incubated with "^^ C-APAP and rat microsomes for 30 min only. After 30 min of 
incubation, 0.287 土 0.018 nmole of APAP was bound covalently to each mg of 
microsomal proteins in controls. This was consistent with the control level in 
covalent binding-time profile study such that 0.212 士 0.030 nmole of APAP was 
covalently bound to each mg of microsomal proteins after 30 min of incubation. 
As shown in Figure 3.10, when 0.1667 mg/ml of PSP was incubated with 
APAP and rat microsomes, the covalent binding had decreased by 25 % of 
controls such that only 0.215 土 0.014 nmole of APAP was bound to each mg of 
microsomal proteins. When a higher concentration of PSP (1.667 mg/ml) was 
incubated with "^^ C-APAP and microsomes, a greater decrease of the covalent 
binding was observed (by 44 % of the control level) and only 0.160 土 0.003 
nmole of APAP was found to bind covalently to each mg of proteins. When PSP 
(33.34 mg/ml) was incubated with '^^ C-APAP and microsomes, the covalent 
binding was 0.107 士 0.004 nmole of APAP/mg of microsomal proteins which had 
decreased by 63 % of controls. Therefore, a dose-dependent decrease of the 
covalent binding was observed with increasing concentrations of PSP. On the 
other hand, as shown in Figure 3.11, when PSP (100 mg/kg/day) was 
administered intraperitoneally into rats for 7 days, the covalent binding of 
APAP to the prepared microsomal proteins in vitro was decreased by 28 %, from 
controls 0.401 土 0.020 to 0.290 士 0.019 nmole of APAP/mg of microsomal 
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Figure 3.10. Concentration-response of PSP on the covalent binding of "^^ C-APAP to rat 
microsomal proteins in vitro. Various concentrations of PSP ( 0.1667-34.34 mg/ml) were 
incubated with i^C-APAP and the prepared microsomes for 30 min. Values represent • 
mean 土 S.E. of six rats. * Indicates significant difference from controls at P < 0.05; *** 
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Figure 3.11. In vivo effects of PSP on the covalent binding of "^^ C-APAP to rat 
microsomal proteins in vitro. PSP (100 mg/kg/day, i.p.) was administered into rats for 7 
days; microsomes were prepared from the PSP-pretreated rats and incubated with C-
APAP for 30 min. Values represent mean 土 S.E. of three to five rats. ** Indicates 
significant difference from controls at P < 0.01. 
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3.3.2 The effects of polysaccharide-peptide (PSP) on the metabolism 
of paracetamol (APAP) 
When APAP (100 mg/kg bolus) was administered intravenously into rats, 
APAP-G and APAP-S were detected in plasma and bile. As shown in Figure 
3.12, the maximum concentration (Cmax) of APAP-G in plasma (15.22 土 1.26 
IIg/ml) was observed at 45 min (T^ax) after administration of APAP; while C a^x 
of APAP-S in plasma (79.18 土 4.50 ^g/ml) was observed at 60 min after APAP 
was administered (Figure 3.13). In bile, T^ax of APAP-G was observed at 45 min 
after APAP was administered with a Cmax of 3935.6 土 531.6 \ig/m\ (Figure 3.14); 
T m a x of APAP-S in bile was observed at 45 min after administration of APAP 
with a Cmax of 907.8 土 157.7 ^ig/ml (Figure 3.15). As shown in Figure 3.16，the 
plasma concentration of APAP declined monoexponentially with time (a log plot 
of plasma concentration of APAP against time generated a straight line with r > 
0.99). The plasma concentrations of APAP were then fit with a one-compartment 
model to determine its pharmacokinetic parameters. The total systemic clearance 
(CLt) of APAP in plasma was 19.06 士 2.74 ml/min/kg, with an apparent volume 
of distribution (V^) of 1.30 士 0.11 L/kg. These results were consistent with those 
of Savina and Brouwer (1992)，who found that CLt and of APAP (100 mg/kg 
bolus, i.v.) were 21.1 土 2.64 ml/min/kg and 1.12 土 0.15 L/kg, respectively. No 
significant changes in metabolic profiles of APAP, APAP-S nor APAP-G in 
plasma and bile were observed after PSP (100 mg/kg bolus, i.v.) was 
administered 30 min before APAP was given. However, when a higher dose of 
PSP (200 mg/kg bolus, i.v.) was administered 30 min before the administration of 
APAP, plasma level of APAP-G was elevated from 60 min onwards after APAP 
was given, with a higher C^x (16.34 士 1.32 pg/ml) and a delayed Tmax (90 min), 
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F:giire 3.12. Concentration-time profiles of paracetamol-glucuronide conjugate (APAP-G 
) in rat plasma during 3 hr after the administration of APAP. PSP ( 100 mg/kg bolus, i.v.) 
( • ) was administered 30 min before APAP ( 100 mg/kg bolus, i.v. ) ( • ) was given. 
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Figure 3.13. Concentration-time profiles of paracetamol-sulphate conjugate (APAP-S ) in 
rat plasma during 3 hr after the administration ofAPAP. PSP ( 100 mg/kg bolus, i .v . ) ( 
• ) was administered 30 min before APAP ( 100 mg/kg bolus, i.v. ) ( • ) was given. 
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Figure 3.14. Concentration-time profiles of paracetamol-glucuronide conjugate (APAP-G 
) in rat bile during 3 hr after the administration of APAP. PSP ( 100 mg/kg bolus, i .v.)( 
• ) was administered 30 min before APAP ( 100 mg/kg bolus, i.v. ) ( • ) was given. 
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Figure 3.15. Concentration-times profiles of paracetamol-sulphate conjugate ( APAP-S ) 
in rat bile during 3 hr after the administration of APAP. PSP (100 mg/kg bolus, i.v.) ( • 
)was administered 30 min before APAP ( 100 mg/kg bolus, i.v. ) ( • ) was given. Values 
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Figure 3.16. Concentration-time profiles of paracetamol ( APAP ) in rat plasma during 3 
hr after the administration of APAP. PSP (100 mg/kg bolus, i.v.) ( • ) was administered 
30 min before APAP ( 100 mg/kg bolus, i.v.) ( • ) was given. Values represent mean 土 
S.E. of six to eight rats. 
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of APAP-G was observed at 120 min after APAP was administered, reaching a 
plasma concentration of 14.53 土 1.05 |ig/ml. Furthermore, as shown in Figure 
3.18, plasma concentration of APAP-S was also increased by the co-
administration of PSP 30 min onwards after APAP was given. The plasma 
concentrations of APAP-S increased with time; 37 % increase at 60 min, 43 % 
increase at 90 min and 47 % increase at 120 min after APAP was administered. 
As shown in Figure 3.19, plasma levels of APAP were decreased with the co-
administration of PSP; CLj increased significantly from controls 19.06 土 2.74 to 
26.22 士 0.84 ml/min/kg, and V^ increased slightly from controls 1.30 士 0.11 to 
1.57 士 0.04 L/kg (P = 0.063) in PSP co-administered rats. In bile, there was little 
effect on APAP-G concentration (Figure 3.20) at PSP (200 mg/kg bolus, i.v.). As 
shown in Figure 3.21, the overall APAP-S levels in bile were much higher when 
PSP (200 mg/kg bolus, i.v.) was administered 30 min before APAP was given. 
The concentration of APAP-S in bile increased 15 min onwards, and 
subsequently became comparable to controls at 180 min after the administration 
of APAP. The T^^x of APAP-S in bile after the co-administration of PSP was the 
same as controls (45 min), but the C^^x increased by 2.4 folds of the control level 
to 3061.0 士 331.6 pg/ml. 
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Figure 3.17. Concentration-time profiles of paracetamol-glucuronide conjugate (APAP-G 
) in rat plasma during 3 hr after the administration ofAPAP. PSP (200 mg/kg bolus, i.v.) 
( • ) was administered 30 min before APAP ( 100 mg/kg bolus, i.v. ) ( • ) was given. 
Values represent mean 土 S.E. of five to eight rats. * Indicates significant difference from 
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Figure 3.18. Concentration-time profiles of paracetamol-sulphate conjugate (APAP-S ) in 
rat plasma during 3 hr after the administration of APAP. PSP ( 200 mg/kg bolus, i .v . ) ( 
• ) was administered 30 min before APAP ( 100 mg/kg bolus, i.v. ) ( • ) was given. 
Values represent mean 土 S.E. of five to eight rats. * Indicates significant difference from 
controls atP< 0.05. 
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Figure 3.19. Concentration-time profiles of paracetamol ( APAP ) in rat plasma during 3 
hr after the administration of APAP. PSP (200 mg/kg bolus, i.v.) ( • ) was administered 
30 min before APAP ( 100 mg/kg bolus, i.v.) ( • ) was given. Values represent mean 土 








5 5000 - T ？、 T ‘ 
I b^^Sv T 
0 4000 - T 
1 T 
2 3000 - h , \ 丄 
鲁 20。。- / ^ N v “ 
， i 〜 
0 - f 1 i 1 1 1 f 1 I ‘ 
0 20 40 60 80 100 120 140 160 180 
Time after administration of APAP ( min ) 
Figure 3.20. Concentration-time profiles of paracetamol-glucuronide conjugate ( APAP-G 
) in rat bile during 3 hr after the administration of APAP. PSP ( 200 mg/kg bolus, i .v . ) ( 
• ) was administered 30 min before APAP ( 100 mg/kg bolus, i.v. ) ( • ) was given. 
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Figure 3.21. Concentration-time profiles of paracetamol-sulphate conjugate (APAP-S ) in 
rat bile during 3 hr after the administration of APAP. PSP (200 mg/kg bolus, i.v. ) ( • ) 
was administered 30 min before APAP ( 100 mg/kg bolus, i.v.) ( • ) was given. Values 
represent mean 土 S.E. of five to eight rats. * Indicates significant difference from controls 
at P < 0.05; ** indicates significant difference from controls at P< 0.01. 
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3.4 Discussions 
As described in section 1.2.1, APAP is rapidly metabolized to the sulphate 
(APAP-S) and glucuronide (APAP-G) conjugates via sulphation and 
glucuronidation, respectively. However, both processes are easily saturable and 
when the dose is so large that the excess amount of the drug wil l be metabolized 
by microsomal cytochrome P450 monooxygenase to form a reactive metabolite, 
A^-acetyl-p-benzoquinoneimine (NAPQI). This reactive metabolite has to be 
detoxified by conjugating with glutathione; otherwise, it wil l cause damages to 
cells by binding to sulphydryl constituents of vital cellular proteins or by 
inducing an oxidative stress (section 1.2.2). The critical doses of APAP which 
wil l generate hepatic damages in Sprague-Dawley rats are 1.0 g/kg orally and > 
0.4 g/kg when APAP is administered intraperitoneally (Siegers et al., 1978). The 
hepatic cytochrome P450 is known to catalyse the oxidative bioactivation of a 
large number of xenobiotics, such as bromobenzene, chloroform and 
benzo(a)pyrene to toxic reactive metabolites (Potter et al., 1973). It has been 
established that the cytochrome P450 monooxygenase enzyme system is 
responsible for the activation of APAP to the chemically-reactive metabolite 
(Jollow et al, 1973; Potter et al., 1973; Hoffmann et aL, 1985; Jeffery et al., 
1988; Reicks et al., 1989; Reicks and Crankshaw, 1993). Isoenzyme specificity 
exists in APAP oxidation. In hamsters, man and the mouse the P450 
cytochromes, I IEl and IA2, have been reported to be the major isoforms 
responsible for hepatic APAP bioactivation, with I IEl accounting for 
approximately 50 % in both mouse liver and kidney (Hu et al., 1993). 
Cytochrome P450 activity has been detected in mitochondria, heavy and light 
microsomes, as well as rough and smooth endoplasmic reticulum. Light 
microsomes contain the highest cytochrome P450 levels followed by heavy 
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microsomes, with much lower amounts in the crude mitochondrial fraction. Al l 
the fractions are capable of metabolizing APAP, and the relative specific 
activities of the subcellular fractions are heavy microsomes greater than light 
microsomes which are, in fact, much greater than mitochondria-rich fraction 
(Snawder et al, 1992). 
Jollow et al (1973) were the pioneers who studied the role of cytochrome 
P450-mediated covalent binding in APAP-induced hepatic necrosis both in vivo 
and in vitro. They found that doses of ^H-APAP that caused necrosis in mice 
were shown to result in large amount of radiolabelled material covalently bound 
to mouse liver protein in vivo (2 nmol/mg of protein or approximately 1 molecule 
bound per 2 molecules of protein in microsomes and cytoplasm). Both covalent 
binding and hepatic necrosis were dose-dependent, and the degree of binding in 
individual mice was always directly proportional to the severity of hepatic 
necrosis. Furthermore, they demonstrated that cytochrome P450 monooxygenase 
mediated the covalent binding of H-APAP to rat and mouse microsomal proteins 
in vitro, as NADPH and oxygen were necessary for the binding while carbon 
monoxide or cobaltous chloride pretreatment inhibited it. On the other hand, the 
binding of H-APAP to rat and mouse microsomal proteins was found to be 
linear with time and with protein concentration, and the binding occurred by 
covalent linkage to amino acids of proteins. 
PSK has been found to decrease the content of cytochrome P450 and 
inhibit the activities of aminopyrine A^-demethylase and aniline hydroxylase in 




protein-bound polysaccharides isolated from Coriolus versicolor, and they share 
great similarities in physico-chemical properties, it will be of great interests to 
investigate the effects of PSP on microsomal enzyme activities. Following the 
protocol of studying the covalent binding of radiolabelled-paracetamol (^ "^ C-
APAP) to microsomal proteins (Potter et al” 1973), both the in vitro and in vivo 
effects of PSP on in vitro covalent binding of "^^ C-APAP to microsomes prepared 
from Sprague-Dawley rats were investigated. In vitro effect of PSP on covalent 
binding-time profile was studied by incubating PSP (16.67 mg/ml) and 
APAP with the prepared microsomes. In this study, the observations on the 
covalent binding of "^^ C-APAP to microsomal proteins in vitro were consistent 
with those of Potter et al (1973), such that less than one nmole of APAP was 
covalently bound to each mg of microsomal proteins (Potter et al., 1973; Roberts 
et aL, 1990; Nasseri-Sina et al., 1992). Furthermore, NADPH was required for 
the covalent binding, and binding of '^^ C-APAP to microsomal proteins increased 
linearly with time until 30 min of incubation (Potter et al, 1973), and attained a 
maximum level thereafter, such that less than 17 % increase of the binding was 
found for further 150 min of incubation. PSP (16.67 mg/ml) inhibited 
significantly the covalent binding of i^C-APAP to microsomal proteins 
throughout the 2-hr period of incubation by 56 % to 79 %. In addition, various 
concentrations of PSP (0.1667-33.34 mg/ml) were incubated with "^^ C-APAP and 
microsomes to investigate the dose-effect of PSP on the covalent binding. Dose-
dependent reductions of covalent bindings of '"^C-APAP to rat microsomes were 
observed, and the bindings had been reduced significantly by 25-63 % with 
increasing concentrations of PSP. The in vitro reduction of covalent binding of 
the chemically-reactive metabolite of "^^ C-APAP to microsomal proteins by PSP 
may due to several possibilities. The prepared rat microsomes contain several 
enzyme systems with the existence of their isoforms. These enzyme systems 
121 
include demethylases, hydroxylases, deethylases and cytochrome P450 
monooxygenases (Prasad et aL, 1990; Snawder et al., 1992; Reicks and 
Cmnkshaw, 1993). Quantitatively, 90 % of the phase I oxidation of xenobiotics is 
catalyzed by the cytochrome P450 monooxygenase enzyme system (Lindamood, 
1991). In man, rats and mice the P450 cytochromes, I IEl and IA2, have been 
reported to be the major isoforms responsible for hepatic APAP bioactivation, 
with I IEl accounting for approximately 70 % (Snawder et al., 1992). In the 
present study, PSP reduced covalent binding of "^^ C-APAP to microsomal 
proteins, and this may due to its inhibitory effects on microsomal enzyme 
activities in vitro. Since the reduction of covalent binding was as great as 63 % of 
controls, cytochrome P450 monooxygenase enzyme system is the most possible 
candidate of being inhibited by PSP, as the enzyme system accounts for most of 
the bioactivation of APAP. Furthermore, since the protein portion of PSP is 
sulphur-containing (section 1.1), the chemically-reactive metabolite of "^^ C-APAP 
may bind directly to PSP so that lesser amount are bound to microsomal proteins; 
or the chemically-reactive metabolite of ''^C-APAP is reduced directly by the 
sulphur constituents of PSP. To investigate the effects of in vivo administration of 
PSP on the covalent binding, microsomes were prepared from PSP pre-treated 
rats and incubated with '"^C-APAP in vitro. The administration of PSP reduced 
covalent binding of '"^C-APAP to the prepared microsomes in vitro by 28 %. 
Since the last dose of PSP was given 6 hr before the rat was sacrificed for 
microsome preparation, there was a possibility that PSP or its metabolite(s) might 
still retain in the microsomal fraction and inhibited the enzyme systems there. 
Another possibility is that the microsome-retained PSP or its metabolite(s) may 
offer alternative binding sites for the chemically-reactive metabolite of ^^C-
APAP, so that it binds less to the microsomal proteins. Furthermore, the sub-
chronic administration of PSP may also reduce the proportion of cytochrome 
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P450 monooxygenase in the prepared microsomes, and results in a decreased 
bioactivation of APAP in vitro. 
Various chemicals or drugs are able to inhibit the activities of cytochrome 
P450 enzymes, and hence reduce the bioactivations of APAP or other 
xenobiotics. The co-administration of drugs that are subject to oxidative 
metabolism by the same enzyme results in competitive, active site inhibitory 
interactions and, depending on the magnitude of this effect, may result in 
impaired drug elimination. Inhibition of drug metabolism is expected in 
situations where another drug interacts with cytochrome P450 at its heme site. 
Reversal of inhibition can occur by metabolism of the inhibitor, or after diffusion 
of the inhibitor away from the enzyme active site. A classical example of this 
reversible inhibition of cytochrome P450 activities is the imidazole-based H2-
receptor antagonist cimetidine (Vermeulen et aL, 1992). Cimetidine appears to 
interact with cytochrome P450 and results in a shift in the spin equilibrium away 
from the high-spin state, a slower rate of electron transfer from NADPH, and 
inhibition of drug metabolism (Murray, 1987). Apart from the reversible 
inhibition of drug oxidation that occurs due to simple active-site interactions with 
ferric cytochrome P450，a number of therapeutic agents undergo metabolic 
activation by the cytochrome P450 system to inhibitory products. These 
metabolic products may generate relatively stable complexes with cytochrome 
P450 so that the cytochrome is sequestered in a functionally inactive state (e.g. 
amphetamines). Alternatively, the metabolite itself may inactivate cytochrome 
P450 via heme or apoprotein modification (e.g. olefins and cyclophosphamide). 
Such the drug-mediated inactivation of cytochrome P450 are irreversible 
(Murray, 1987). Because of the unknown chemical structure and metabolic 
« 
123 
pathways of PSP, it is not known whether PSP may inhibit cytochrome P450 
monooxygenase in a reversible or an irreversible manner. PSP, like cimetidine, 
may behave as an inhibitor which competes with APAP for the heme active site 
of cytochrome P450; or PSP, like amphetamines or olefins, may either form 
stable complexes with cytochrome P450 or induce irreversible heme or 
apoprotein modification leading to autocatalytic inactivation, or suicide 
processing of cytochrome P450. Up to the present moment, the exact inhibitory 
mechanism(s) of PSP or/and its metabolite(s) on covalent binding of i^C-APAP 
to microsomal proteins is not known and needs further investigation. 
Excretion of a xenobiotic from an animal generally requires the 
conversion of the xenobiotic to a more water soluble metabolite. Both sulphation 
and glucuronidation are important processes in the metabolism of xenobiotics and 
endogenous substances, leading to the generations of their water-soluble 
metabolites and enhancement of excretions of these compounds into the urine or 
bile ultimately out of the body. The conventional view has it that conjugation 
reactions proceed in the second of a two-phase sequence: oxidation (phase 1), 
where a substance may be hydroxylated, followed by sulphation or 
glucuronidation (phase 2). However, many drugs and environmental chemicals 
already exist in the hydroxylated state when the animal is exposed. This is the 
case of APAP, which needs not to be converted by other metabolic reactions in 
order to serve as substrates for sulphate or glucuronide formation. Therefore, 
both sulphation and glucuronidation serve as the first-line reactions in the 
metabolism of APAP. When APAP is administered into animals, it wi l l be 
rapidly absorbed. At 30 min after an oral administration of APAP (500 mg/kg), 
only 30 % of the administered dose of APAP could be recovered from the 
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gastrointestinal tract, and peak concentrations of APAP were already high in liver 
and kidney (1500-2000 nmol/g) after 1 hr (Fischer et al., 1981). After the rapid 
absorption, APAP wil l be extensively metabolized to glucuronide (APAP-G) and 
sulphate (APAP-S) conjugates (Howie et al., 1977; Rashed and Nelson, 1989; 
Rustum, 1989; Scott et al, 1990; Esten and Graells，1991). 
Sulphation is an important metabolic pathway in the biotransformation of 
various xenobiotics and many endogenous compounds such as neurotransmitters, 
steroid hormones, peptides and bile acids. The process is catalyzed by the 
sulphotransfrases, a group of soluble enzymes found primarily in liver, kidney, 
intestinal tract and lung. These enzymes catalyse the formation of sulphate esters 
with 3丨-phosphoadenosine 5'-phosphosulphate (PAPS) as the sulphate donor. On 
the other hand, PAPS is formed in a 2-step reaction from ATP and inorganic 
sulphate, catalyzed by ATP sulphurylase and adenosine 5,-phosphosulphate 
(APS) kinase as shown in Figure 3.22 (Kim et al, 1992). Sulphotransferase 
enzyme is usually depicted as a high-affinity, low capacity enzyme system which 
wi l l become increasingly underrepresented at higher substrate concentrations. For 
example, when increasing doses of APAP were administered in vivo to hamsters, 
the percentage of urinary metabolites represented by the sulphate conjugate 
would begin to decrease at dose levels over 100 mg/kg (Jollow et aL, 1973). In 
fact, rats show a higher capacity of sulphotransferase activity than hamsters as 
the percentage of urinary APAP-S wil l fall only at the 400 mg/kg dose level. 
Miller et al (1993) used liver slices as predictive models for studying the in vivo 
metabolism and toxicity of APAP. They found that the relative capacity of the 
liver slices to form APAP-S and APAP-G were different between hamster and 
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Figure 3.22. Sulphate activation and sulphation of paracetamol (APAP). 
3'-phosphoadenosine 5'-phosphosulphate (PAPS) is formed in a two-step 
reaction from ATP and inorganic sulphate, catalysed by ATP-sulphurylase and 
adenosine 5,-phosphosuIphate (APS) kinase. Sulphation occurs at the hydroxyl 
group of APAP catalysed by sulphoti-ansferase. 1: ATP sulphurylase. 2: APS 
kinase. 3: Phenol sulphotransferase (adapted from Kim et al, 1992). 
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predominant conjugation pathway in the rat was sulphation. They concluded that 
in hamster, the enzyme kinetic considerations are of greater importance than 
sulphate availability in governing APAP sulphotransferase activity; whereas the 
kinetic considerations are less important for the rats，and the availability of 
sulphate for co-substrate synthesis plays an important role in capacity limitation 
at high dose levels. 
Glucuronidation is catalyzed by a family of enzymes, the UDP-
glucuronosyltransferases (UDPGTs). UDPGTs possess molecular weights 
between 50 and 60 kDa and are located in the endoplasmic reticulum of cells 
from a number of tissue, including rat kidney, lung and spleen, but are usually 
found in highest activity in the liver. These proteins are extremely labile after 
membrane perturbation and are dependent upon phospholipid for activity. 
Topologically, UDPGTs share a small C-terminal domain exposed on the 
cytoplasmic surface of the membrane, and is joined by a transmembrane region 
to the majority of the protein, including the active site, on the lumen of the 
endoplasmic reticulum (Figure 3.23). Structurally, UDPGTs possess at least one 
putative asparagine-linked glycosylation consensus sequence (Asn-X-Ser/Thr) in 
the translated protein. Al l the isoenzymes possess hydrophobic (cleaved) signal 
sequences and a highly hydrophobic sequence in the C-terminal region, located 
between two highly charged areas. Furthermore, lysine residues at position -3, -4 
and -5 from the C-terminus are important in retention of UDPGTs in proper 
orientation in the endoplasmic reticulum (Tephly and Burchell, 1990). Discrete 
specificities have evolved in UDPGTs in response to the need to eliminate 
potentially toxic endobiotic and environmentally produced xenobiotic 
compounds (Tephly and Burchell, 1990). Human and rat express phenol UDP-
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Figure 3.23. Model of the topology of UDP-glucuronosyltransferase 
(UDPGTs). A small C-terminal domain is exposed on the cytoplasmic 
surface of the membrane, and is joined by transmembrane region to the 
majority of the protein, including the active site, on the lumen of the 
endoplasmic reticulum, a: UDP-glucuronic acid (UDPGA) binding domain, 
conserved sequence, b: Xenobiotic or endobiotic substrate-binding region, 
variable sequence, c: N-terminal region, conserved sequence. Lys^Lys: stop 
transfer sequence (adapted from Tephly and Burchell, 1990) 
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glucuronosyltransferases of the UDPGTl complex (Hlug PI, Hlug P4 and rat 
UDPGTIAI, the latter considered to be an orthologous enzyme to Hlug PI). 
APAP is found to be an overlapping substrate of several UDPGTs, showing 
higher affinity for Hlug PI and UDPGTIAI (apparent K^ values of 2 and 3 it iM 
respectively) than for Hlug P4 {K^: 50 mM) and other UDPGTs present in liver 
microsomes (K^ values of > 12 mM) (Bock et aL, 1993). 
In the present study, doses of PSP (100 or 200 mg/kg bolus) were 
administered intravenously into rats followed by APAP (100 mg/kg bolus, i.v.) 
30 min later. Plasma level of APAP, as well as plasma and biliary levels of 
APAP-S and APAP-G were monitored throughout 3 hr after the administration of 
APAP. When APAP was administered into rats, both APAP-S and APAP-G 
conjugates were found in plasma and bile. In plasma, the predominant metabolite 
was APAP-S with Cmax (0.342 土 0.052 |iimol/ml) found at 60 min, but the C^ax of 
APAP-G was only 0.047 土 0.010 |imol/ml at 45 min after APAP was 
administered. Therefore, the maximum plasma concentration of APAP-S was 
about 7 folds higher than that of APAP-G. However，in biliary dispositions of 
APAP metabolites, reversal of the above phenomenon was observed such that the 
predominant metabolite was APAP-G (Cmax was 11.94 ± 4.11 \imo\/m\ at 45 min) 
rather than APAP-S (Cmax was 3.92 土 1.80 ^mol/ml at 45 min). The above 
observations were consistent with those of Kim et al. (1992) who found that the 
predominant metabolite of APAP in serum 2 hr after administration of the lower 
dosages of APAP, i.p., up to 150 mg/kg was APAP-S, and APAP-G was the 
predominant metabolite in bile. Although it was not shown in present study, Kim 
et al. (1992) also found that APAP-S concentration in serum would exhibit a 
plateau at the dosage of 75 mg/kg of APAP but not the serum level of APAP-G, 
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and biliary excretion of APAP-S would reach a plateau at 300 mg/kg dosage of 
APAP. No significant change of the metabolic profile of APAP in plasma nor 
metabolic profiles of APAP-S and APAP-G in both plasma and bile were 
observed at 100 mg/kg of PSP treatment. However, a higher dose of PSP (200 
mg/kg) induced significant changes of metabolic profiles of APAP and its 
metabolites in both plasma and bile. The plasma concentration of APAP was 
lower, and CL j was increased after the co-administration of PSP. The V^ also 
increased after the PSP co-administration but this increase did not attain 
statistically significant level (P = 0.063). These results indicated that the co-
administration of PSP could increase the clearance of APAP, as well as a higher 
localization of APAP in peripheral tissues. In this study, a one-compartment open 
model was selected to investigate the plasma concentration-time profiles of 
APAP, although multi-compartment open model have been suggested elsewhere 
(Siegers et a!., 1978; Tone et al., 1990; Brouwer, 1993; Studenberg and Brouwer, 
1993). A one-compartment open model was selected because adequate 
description of a distributive phase was not possible from the early time points, 
and the one-compartment model has also be used in other studies (Galinsky and 
Chalasinska, 1987; Savina and Brouwer, 1992; Studenberg and Brouwer, 1993). 
Complementary to the lower plasma level of APAP after the PSP co-
administration, there were higher levels of APAP-G in plasma as well as higher 
levels of APAP-S in plasma and bile. The co-administration of PSP induced 
elevations of plasma levels of APAP-G from 60 min onwards until the end of 
study. A statistically significant elevation of plasma level of APAP-G (increased 
by 34 % of controls) was detected at 120 min after APAP was administered. On 
the other hand, the PSP co-administration elevated the plasma concentrations of 
APAP-S from 30 min onwards after APAP was administered. Statistically 
significant elevations of APAP-S plasma concentrations were found at 60，90 and 
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120 min, respectively, after the administration of APAP. In biliary disposition of 
APAP-S, bile concentration of the metabolite was significantly increased after 
the PSP co-administration from 15 min onwards, and became comparable to 
controls at 165 min after APAP was given. Statistically significant elevations of 
bile APAP-S levels were observed at 45，75 and 90 min, with respective 
increases of 2.4, 1.8 and 1.5 folds of the control level. However, the co-
administration of PSP had no prominent effect on biliary disposition of APAP-G. 
The rate of glucuronidation in situ is influenced by the absolute amount of 
UDPGT and the content of its cofactor, UDP-glucuronic acid (UDPGA). 
Oxidation of the alcohol group on C-6 of D-glucose to a carboxylic group yields 
D-glucuronic acid. The production of glucuronic acid is by a metabolic route that 
branches off from glycogenesis, the compound at the branch point being uridine 
diphosphoglucose (UDP-glucose). The UDP-glucose is then converted to 
UDPGA by the enzyme UDP-glucose dehydrogenase (UDP-GDH) with NAD 
being reduced in the process (Figure 3.24; Bowan and Rand, 1980). Reen et al 
(1993) showed that piperine (1-piperoyl piperidine, a major ingredient of black 
pepper) non-competitively inhibited UDP-GDH derived from both guinea pig 
small intestine and rat liver. The depleted level of UDPGA then resulted in 
retarded glucuronidation of 3 -hydroxybenzo[a]pyrene. Furthermore, UDPGA 
transport is rate limiting for glucuronidation by intact microsomes, and that 
disruption of the membrane barrier by detergents wi l l allow free access of the 
donor substrate and reveals the full catalytic potential of the transferases (Tephly 
and Burchell, 1990). Miners et al. (1990) added non-ionic detergent Brij 58 to 
microsomal incubations and resulted in approximately 50 % activation of 
microsomal UDPGT activity towards APAP. In present study, pretreatment with 
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Figure 3.24. Formation of UDP-glucuronic acid (UDPGA) and glucuronide 
conjugates (adapted from Bowman and Rand, 1980). 
« 
132 
PSP (200 mg/kg) elevated plasma concentration of APAP-G, and since the rate of 
glucuronidation is rate-limited by both the activity of UDPGT and the supply of 
UDPGA, PSP may affect either or both of these aspects. Studenberg and Brouwer 
(1993) found that in vivo phenobarbital treatment induced significantly the 
UDPGT activity towards APAP. Liu et al (1993) found that oleanolic acid, a 
triterpenoid compound that has been used in China to treat hepatitis, could 
increase hepatic UDPGT activity toward APAP together with increased urinary 
excretion of APAP-G. However, no influence of oleanolic acid on liver UDPGA 
concentration was detected. PSP may increase the amount or activity of UDP-
GDH, and hence the supply of UDPGA for glucuronidation; or like phenobarbital 
and oleanolic acid, PSP may differentially increase the UDPGT activity towards 
APAP, and hence the generation of APAP-G and its discharge into plasma. Al l 
these possibilities can not be ruled out and need further investigation. 
Generally, sulphation is considered to have a high affinity but low 
capacity for conjugation of phenols, and the sulphation of APAP is considered to 
have a higher affinity but a lower capacity than its glucuronidation (Jollow et al., 
1973). As discussed before, sulphation is catalyzed by sulphotransferases which 
involve the formation of sulphate esters with the hydroxyl group of the 
xenobiotic and the sulphate donor, 3 '-phosphoadenosine 5'-phosphosulphate 
(PAPS). PAPS is present in very low concentrations but may be synthesized very 
rapidly. The overall process of sulphation is thought to be limited by the 
availability of the PAPS precursor, inorganic sulphate, which is obtained from 
absorption from the intestinal tract and the oxidation of cysteine. APAP dosages 
between 150 to 600 mg/kg, i.p., 2 hr after dosing depleted 60 to 80 % of hepatic 
PAPS (Kim et al., 1992). Hepatic PAPS levels returned to control values 16 to 20 
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hr after dosing with 600 mg/kg of APAP. APAP also decreased serum sulphate to 
a similar degree (80 %) and duration (16 hr) as did hepatic PAPS. APAP also 
lowered sulphate concentrations in liver but to a somewhat lesser extent (65 %) 
than in serum. Hepatic sulphate levels returned to control values at 16 to 24 hr 
after dosing with APAP. Al l these findings indicated that the capacity-limited 
sulphation of APAP is due to the limited availability of hepatic PAPS, which in 
turn is limited by the availability of sulphate in liver. The increased plasma level 
and biliary disposition of APAP-S after the co-administration of PSP may, 
probably, due to the increased supply of PAPS for sulphation to occur. As 
described in section 2.3.2, PSP (300 mg/kg, i.p.) depleted hepatic glutathione, 
and this depletion may contribute to a certain extent to the incidence of increased 
sulphation of APAP. Both sulphation and glutathione conjugation share cysteine 
as a common precursor. Inorganic sulphate deriving from cysteine is activated by 
formation of the coenzyme PAPS preceding the conjugation reaction catalyzed 
by phenolsulphotransferase. On the other hand, the y-glutamyl cycle utilizes 
cysteine in formation of glutathione, which is a substrate for glutathione-5'-
transferases, the enzymes catalyzing the conjugation reaction. In the present 
study, it is possible that PSP inhibited the y-glutamyl cycle, and resulted in an 
accumulation of cysteine. The increased hepatic level of cysteine then stimulated 
the synthesis of PAPS, and hence a higher incidence of sulphation was occurred. 
This postulation was supported by the findings of Dalhoff and Poulsen (1993b,c) 
that sulphation and glutathione conjugation were regulated by cysteine, 
depending on the concentration of APAP to be detoxified. A 4-fold increase in 
PAPS synthesis, irrespective of APAP concentration, was found when 
glutathione synthesis was inhibited. These results indicated that more sulphur 
from cysteine was available compared to situations with intact glutathione 
synthesis. They postulated that the effect on PAPS synthesis was the result of 
« 
134 
increased PAPS turnover rates rather than increased PAPS concentration. 
Therefore, PSP or/and its metabolite(s) may inhibit the y-glutamyl cycle and 
results in the accumulation of cysteine. The elevated cysteine level then 
stimulates synthesis of PAPS and results in increased sulphation of APAP. When 
PSP (200 mg/kg bolus, i.v.) was administered 30 min after the intravenous 
administration of APAP, no significant change of the metabolic profiles of APAP 
or its metabolites could be observed in either plasma or bile (not shown), 
indicating the importance of the time interval between the administrations of PSP 
and APAP. Time may be required for the inhibition of y-glutamyl cycle by PSP 
or its metabolite(s) and the direction of elevated level of cysteine for PAPS 
synthesis. In fact, when PSP (200 mg/kg) was administered 30 min before APAP 
was given, significant increases in plasma levels of APAP-G were occurred only 
150 min after PSP was administered, and significant increases in plasma and bile 
APAP-S levels were observed only 90 and 75 min, respectively, after the 
administration of PSP. Dalhoff and Poulsen (1993b,c) demonstrated that a pre-
incubation of the isolated hepatocytes with 10 mM buthionine sulphoximine (a 
specific inhibitor of glutathione biosynthesis) for 30 min would deplete 
glutathione by 38 % and PAPS by 27 %. The depletion then resulted in increased 
PAPS synthesis at both non-toxic and toxic APAP concentrations. Similarly, PSP 
may have to be administered 30 min before that of APAP so that significant 
changes of plasma and bile concentrations of APAP-S and APAP-G could be 
observed. 
In this study, PSP reduced covalent binding of '"^C-APAP to rat 
microsomal proteins in vitro when PSP was administered either in vitro or in 
vivo. PSP-induced reduction of the covalent binding may serve as an important 
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protective mechanism, since binding of the chemically-reactive metabolite of 
APAP to cell macromolecules is an important mean which leads to necrosis of 
hepatocytes. In addition, the co-administration of PSP with APAP elevated 
sulphate and glucuronide conjugate levels in plasma and bile, indicating that PSP 
may also protect against APAP-hepatotoxicity by enhancing sulphation and 
glucuronidation of APAP. The increased sulphation and glucuronidation of 
APAP are important first-line defense which eliminate APAP before it is 






In this study PSP protected against APAP-hepatotoxicity in the rat and the 
mouse by decreasing the APAP-induced elevation of aminotransaminases in 
plasma (Figures 2.05, 2.06 and 2.07, respectively). This indicated that PSP, being 
a novel immunomodulatory agent, was also protective on the hepatocytes^ Unlike 
other protective agents, such as //-acetyl-L-cysteine or methionine which increase 
hepatic glutathione levels and subsequently conjugates with the reactive 
metabolite of APAP, acute administration of PSP decreased hepatic total 
glutathione (GSH + GSSG) and reduced glutathione (GSH) levels (Figures 2.12 
and 2.13, respectively) and induced a certain degree of oxidative stress in the 
liver (Figure 2.15). With the loss of glutathione in liver, blood glutathione levels 
were slightly elevated after PSP administration (Figures 2.16, 2.17 and 2.18, 
respectively) indicating that PSP might increase the sinusoidal export of 
glutathione from liver, mainly in form of GSSG, into systemic circulation. Sub-
chronic administrations of high doses of PSP showed similar effects on 
glutathione levels in liver. However, when lower doses of PSP were administered 
sub-chronically into rats, hepatic total glutathione (GSH + GSSG) levels were 
slightly affected but GSH levels were decreased accompanying by an elevated 
GSSG levels in liver. Therefore, contrary to the expectation that as an 
immunomodulatory agent PSP should maintain a steady level of glutathione for 
the proper ftinctioning of immune system, PSP decreased glutathione levels in the 
liver. The decreases of hepatic glutathione levels after PSP administrations may 
due to several possibilities; the enhanced exports of glutathione from liver into 
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systemic circulation, the direct conjugation of PSP with glutathione, the 
inhibition of glutathione synthesis or perturbation of the GSH-related enzyme 
activities. 
Overdosage of APAP depletes glutathione levels in liver, and the excess 
APAP is bioactivated to the chemically-reactive metabolite causing damage to 
cells. It has been shown that the maintenance of a steady level of hepatic 
glutathione is important in the detoxification of APAP. In this study when PSP 
was co-administered with APAP, the APAP-induced depletions of glutathione 
levels were not elevated by PSP (Figures 2.08 and 2.09, respectively). This 
suggests that the protective mechanism of PSP against APAP-hepatotoxicity is 
unlikely to be related to the glutathione concentrations available for the 
conjugation of the reactive metabolite of APAP. When PSP was co-administered 
with APAP the oxidative stress in liver was significantly decreased (Figure 2.11)， 
and this might be the mechanism through which PSP decreased the damage on 
hepatocytes caused by overdosage of APAP. 
PSP decreased the covalent binding of APAP to microsomal proteins in 
vitro dose-dependently (Figures 3.09 and 3.10’ respectively). When PSP was 
administered sub-chronically into rats, the covalent binding was again decreased 
(Figure 3.11). Therefore, PSP may conjugate directly to the reactive metabolite of 
APAP in vitro as PSP is a protein-bound polysaccharide and its protein portion 
composes of sulphur-containing amino acids, including cystine and methionine. 
However, the sub-chronic study showed that PSP may have caused both 
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qualitative and/or quantitative changes on the microsomal proteins, or in the 
generation of the chemically-reactive metabolite. 
Biotransformation can be a detoxification process which, in general, 
converts poorly excretable lipophilic xenobiotics to readily excretable water-
soluble compounds. For the metabolism of APAP, the drug is conjugated to 
sulphate or glucuronide before it is excreted. Excess amount of APAP wil l be 
oxidized by cytochrome P450 monooxygenase to form NAPQI which may 
conjugate with glutathione, or in overdoses, wil l bind covalently to 
macromolecules and causes -damage to cells. Therefore, sulphation and 
glucuronidation are important conjugations which serve as first-line defense 
against APAP-hepatotoxicity. In this study, PSP increased both sulphation and 
glucuronidation of APAP with elevated concentration of sulphate and 
glucuronide conjugates being found in plasma and bile (Figures 3.18, 3.19 and 
3.21, respectively). The increased sulphation and glucuronidation by PSP may 
due to several mechanisms; PSP may increase the activities of enzymes 
catalyzing the above reactions, or it may increase the supplies of the co-factors 
for sulphation and glucuronidation to occur. The increased sulphation and 
glucuronidation are important protective mechanisms of PSP against APAP-
hepatotoxicity since the enhanced processes wil l eliminate APAP more so that 
lesser amount of APAP may be activated by cytochrome P450 and causes 
damage to cells. 
The present study offers some preliminary information on the 
pharmacological effects of PSP on the biotransforming reactions of xenobiotics. 
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PSP was protective against APAP-induced hepatotoxicity in rats and mice, as 
indicated by reduced discharges of aminotransaminases into blood. It is possible 
that a higher integrity of the liver is maintained by PSP co-administration. From 
the present results, it was unlikely that the protective action of PSP was mediated 
through direct conjugation of the reactive metabolite of APAP with glutathione, 
as PSP co-administration did not increase APAP-induced depletion of hepatic 
glutathione levels, and when PSP was administered alone it depleted hepatic 
glutathione levels as well. However, the co-administration of PSP with APAP 
reduced the oxidative stress in the liver and this might be an important event to 
protect liver against damage caused by overdosage of APAP. In addition, PSP 
reduced the covalent binding of APAP to microsomal proteins, and when PSP 
was co-administered with APAP both the sulphation and glucuronidation of 
APAP were increased. Although PSP administration depleted hepatic glutathione 
levels and induced a certain extent of oxidative stress in liver, these processes 
might exist as the intermediate steps for PSP to generate protection against 
APAP-toxicity. Since glutathione conjugation and sulphation of APAP share 
cysteine as a common precursor, the PSP-induced depletion of glutathione may 
increase the supply of co-factor for sulphation of APAP to occur and protects 
liver against the toxicity. 
Further studies are required for a better understanding of the 
pharmacological effects of PSP as the present study offers only some preliminary 
insights on the effects of PSP on the metabolism and toxicity of APAP. The 
preliminary results showed that PSP depleted hepatic glutathione levels and 
induced a certain degree of oxidative stress in the liver. It wil l be of interests to 
investigate the effects of PSP on the glutathione-related enzyme activities, 
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including glutathione reductase, glutathione peroxidase and glutathione-iS-
transferase (Yeung, 1991; Aniya et aL, 1993; Armesto et aL, 1993). In this study 
co-administration of PSP with APAP reduced oxidative stress in liver, and this 
might be an important mean of hepatoprotection. The antioxidant properties of 
PSP can be investigated fiirther by studying its effects on lipid peroxidation when 
PSP is co-administered with other oxidants, like tetrachloromethane (Muriel et 
al., 1992). Furthermore, since the co-administration of PSP increased sulphation 
of APAP, the effects of PSP on homeostasis of sulphate and 3'-phosphoadenosine 
5'-phosphosulphate (PAPS) in serum and liver (Kim et aL, 1992), as well as its 
effects on sulphotransferase (Woodhouse and Herd, 1992) had to be considered. 
Whether or not PSP may inhibit the glutathione synthesis so as to increase the 
sulphation of APAP, simultaneous measurement of PSP effects on glutathione 
and PAPS synthesis rates as well as their conjugations of APAP (Dalhoff and 
Poulsen, 1993) can offer us further insights into this possible mechanism. 
Experiments on the effects of PSP on UDP-glucose dehydrogenase and UDP-
glucuronosyltransferase activities (Bock et al., 1993; Reen et al., 1993) may also 
provide some information on the mechanism(s) of the increased glucuronidation 
of APAP by PSP. In this study PSP decreased the covalent binding of ^"^C-APAP 
to microsomal proteins in vitro, and it wil l be of interests to study the effects of 
PSP on the in vivo covalent binding as well (Fischer et aL, 1981). A l l the above 
suggested studies should offer us a more complete view on the possible 
cytoprotective mechanisms of PSP, and merit further investigation before PSP 
can be widely used as an adjuvant in cancer chemotherapy. 
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